triazoles has been researched along with Diabetes Mellitus, Type 2 in 559 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.18) | 18.2507 |
| 2000's | 142 (25.40) | 29.6817 |
| 2010's | 402 (71.91) | 24.3611 |
| 2020's | 14 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Carr, CA; Castro-Guarda, M; Dennis, KMJH; Heather, LC; Massourides, E; Montes Aparicio, CN; Purnama, U; Sousa Fialho, MDL; Tyler, DJ | 1 |
| Buil, JB; den Dekker, BM; Festen, B; Heusinkveld, M; Melchers, M; Mooren, ERM; Schellaars, R; van Binsbergen, AL; van Bree, SHW; van Zanten, ARH; Verweij, PE | 1 |
| Akbarzadeh, T; Faramarzi, MA; Iraji, A; Mojtabavi, S; Saeedi, M; Shareghi-Brojeni, D | 1 |
| Bayannavar, PK; Bheemayya, L; Hoolageri, SR; Joshi, SD; Kamble, RR; Kodasi, B; Kumbar, VM; Metre, TV; Nadoni, VB; Shettar, AK | 1 |
| Cui, ZN; Fu, C; He, M; Li, YJ; Li, YS; Shao, J | 1 |
| Emadi, M; Faramarzi, MA; Ghadimi, R; Halimi, M; Hosseini, S; Mahdavi, M; Moazzam, A; Moghadamnia, AA; Mohammadi-Khanaposhtani, M; Mojtabavi, S; Nasli-Esfahani, E | 1 |
| Amanlou, M; Asadi, M; Faramarzi, MA; Halimi, M; Larijani, B; Mahdavi, M; Moazzam, A; Mohammadi-Khanaposhtani, M; Mohammadi-Moghadam-Goozali, M; Mojtabavi, S; Sayahi, MH; Yousefnejad, F | 1 |
| Chen, Y; Ignacimuthu, S; Kandhasamy, S; Kannan, BS; Kim, Y; Palani, P; Shao, Q; Stalin, A; Verma, RS | 1 |
| Fernandez, E; Makar, G; Perz, A; Rafferty, W; Weinstock, J | 1 |
| Chen, C; Ge, M; Liao, H; Liu, D; Pan, L; Shen, N; Wu, S; Yao, W | 1 |
| Bouslama, R; Chi, NW; Dumont, V; Krauss, S; Kuusela, S; Lehtonen, S; Linden, AM; Pirinen, E; Ramadan, UA; Rinnankoski-Tuikka, R; Waaler, J; Wang, H | 1 |
| Ando, Y; Hirose, T; Kumashiro, N; Miyagi, M; Shigiyama, F; Uchino, H; Yoshikawa, F | 1 |
| Mu, J; Tian, Y; Xie, Z; Zhang, D; Zou, MH | 1 |
| Kobayashi, T; Okada, T; Suda, S; Takano, M | 1 |
| Bokor, É; Chatzileontiadou, DSM; Kantsadi, AL; Kun, S; Kyriakis, E; Leonidas, DD; Solovou, TGA; Somsák, L; Stravodimos, GA | 1 |
| Adams, LA; Bouaichi, C; Cabrera, O; Campbell, AN; Cardona, GR; Chen, K; Chen, Y; Cr, S; DeBaillie, AC; Diseroad, BA; Hamdouchi, C; Kahl, SD; Lineswala, JP; Ma, X; Maiti, P; Miller, AR; Montrose-Rafizadeh, C; Neathery, GL; Otto, KA; Patel Lewis, A; Sweetana, SA; Warshawsky, AM; Wilbur, KL; Yumibe, NP; Zink, RW | 1 |
| Fukudome, H; Hosaka, M; Ishii, H; Kawano, T; Koike, T; Kurosawa, K; Mimasu, S; Moritomo, A; Sasuga, D; Shiraki, R; Yoshimura, S | 1 |
| Miyazaki, S; Mori, Y; Taniguchi, Y; Utsunomiya, K; Yokoyama, J | 1 |
| Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F | 2 |
| Gondo, S; Hiwatashi, A; Ikeda, H; Inoue, T; Iwamoto, T; Kodama, K; Kuroki, S; Node, K; Oyama, J; Sakamoto, Y; Shimomura, M; Taguchi, I; Uchida, Y | 1 |
| Banks, P; Ding, ZM; Frazier, K; Freiman, J; Ogbaa, I; Powell, D; Ruff, D; Sands, A; Smith, M; Turnage, A; Zambrowicz, B | 1 |
| Cadelis, G | 1 |
| Bartola, LD; Giampietro, C; Giampietro, O; Masoni, MC; Matteucci, E | 1 |
| Chang, HY; Clark, JM; Richards, TM; Segal, JB; Singh, S; Weiner, JP | 1 |
| Cohen, D | 1 |
| Blétry, O; Bouilloud, F; Crickx, E; Kahn, JE; Le Beller, C; Marroun, I; Schoindre, Y; Veyrie, C | 1 |
| Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M | 1 |
| Grunberger, G | 1 |
| Flessner, MF; St Peter, WL; Weinhandl, ED | 2 |
| Drake, AJ; Iyer, SN; Mendez, CE; Tanenberg, RJ; West, RL | 1 |
| Atkinson, M; Butler, AE; Butler, PC; Campbell-Thompson, M; Dawson, DW; Gurlo, T | 1 |
| Ayaori, M; Iizuka, M; Ikewaki, K; Iwakami, N; Komatsu, T; Murakami, T; Nakaya, K; Ogura, M; Sasaki, M; Sato, H; Takase, B; Takiguchi, S; Uto-Kondo, H; Yakushiji, E; Yogo, M | 1 |
| Gavish, D; Gevrielov-Yusim, N; Goldenberg, I; Gottlieb, S; Leibovitz, E; Matetzky, S | 1 |
| Hunt, B; Langer, J; Valentine, WJ | 1 |
| Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J | 1 |
| Alexander, CM; Brodovicz, KG; Engel, SS; Girman, CJ; Kou, TD; O'Neill, EA; Senderak, M | 1 |
| Ishibashi, S; Kotani, K; Nagashima, S; Okada, K; Osuga, J; Ozaki, K; Takahashi, M; Yagyu, H; Yamazaki, H | 1 |
| Bhargava, A; Del Prato, S; Dharmalingam, M; Garber, AJ; Philis-Tsimikas, A; Rasmussen, S; Satman, I; Skjøth, TV | 1 |
| Adams, J; Cersosimo, E; DeFronzo, RA; Garduno-Garcia, Jde J; Solis-Herrera, C; Triplitt, C | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H | 1 |
| Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L | 1 |
| Asche, CV; Eurich, DT; McAlister, FA; Sandhu-Minhas, JK; Senthilselvan, A; Simpson, S | 1 |
| Ando, K; Morimoto, A; Nishimura, R; Sakamoto, M; Seo, C; Tsujino, D; Utsunomiya, K | 1 |
| Tang, Y; Wu, F; Xu, T; Zhan, M | 1 |
| Segal, J | 1 |
| Schütt, M; Steinhoff, J; Süfke, S | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Gao, H; Hu, J; Sun, R; Wang, F; Wang, L; Wang, Y; Wang, Z; Yan, S; Yu, X; Zhao, W | 1 |
| Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D | 1 |
| Bergeson, JG; Graham, J; Louder, A; Ward, M; Worley, K | 1 |
| Batra, M; Chaudhuri, A; Dandona, P; Kuhadiya, N; Makdissi, A | 1 |
| Bruce, SS; Connolly, ES; Heyer, EJ; Mergeche, JL | 1 |
| Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S | 1 |
| de Oliveira, JM | 1 |
| Eurich, DT | 1 |
| Scheen, AJ | 8 |
| Han, J; Malloy, J; Meloni, A | 1 |
| Bae, JH; Cho, YM; Jung, HS; Kim, SY; Kim, YG; Oh, TJ; Park, KS | 1 |
| Ahrén, B; Alba, M; Goldstein, BJ; Guan, Y; Inzucchi, SE; Kaufman, KD; Mallick, M; O'Neill, EA; Williams-Herman, DE; Xu, L | 1 |
| Moniri, NH; Ryan, GJ; Smiley, DD | 1 |
| Behera, A; Bhansali, A; Chakrabarti, A; De, D; Dutta, P; Premkumar, A; Rudramurthy, SM; Shah, VN | 1 |
| Cander, S; Cinkilic, N; Ersoy, C; Gul, CB; Oz Gul, O; Tuncel, E; Vatan, O; Yılmaz, D | 1 |
| Farrokhi, F; Gianchandani, R; Jacobs, S; Lathkar-Pradhan, S; Newton, C; Pasquel, F; Peng, L; Reyes, D; Smiley, D; Umpierrez, GE; Wesorick, DH | 1 |
| Huang, Q; Peng, Y; Wang, Y; Zhao, L | 1 |
| Chou, MZ; Fonseca, VA; Goldstein, BJ; Golm, GT; Henry, RR; Kaufman, KD; Langdon, RB; Staels, B; Steinberg, H; Teng, R | 1 |
| Araki, E; Furukawa, N; Goto, R; Ichimori, S; Iwashita, S; Kawashima, J; Kondo, T; Maeda, T; Matsumura, T; Matsuo, T; Matsuo, Y; Motoshima, H; Nishida, K; Sekigami, T; Shimoda, S | 1 |
| Du, Q; Liang, YY; Wang, YJ; Wu, B; Yang, S; Zhao, YY | 1 |
| Harja, E; Lord, J; Skyler, JS | 1 |
| Dang, NH; Hatano, R; Morimoto, C; Ninomiya, H; Ohnuma, K; Saito, T; Suzuki, H | 1 |
| Derosa, G; Maffioli, P | 2 |
| Arjona Ferreira, JC; Goldstein, BJ; Golm, GT | 1 |
| Andersson, C; Mogensen, UM; Scheller, NM; Torp-Pedersen, C; Vaag, A | 1 |
| Epstein, S; Gallagher, EJ; Kornhauser, C; LeRoith, D; Sun, H; Tobin-Hess, A; Yakar, S | 1 |
| Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C | 1 |
| Bain, SC; Eligar, VS | 1 |
| Cho, JH; Kim, ES; Kim, HS; Lee, SH; Shin, JA; Son, HY; Yoon, KH | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C | 1 |
| Kawata, T; Matsubara, F; Nagai, Y; Nakamura, Y; Ohshige, T; Ohta, A; Sakai, K; Tanaka, Y; Tenjin, A; Terashima, Y; Tsukiyama, S | 1 |
| Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F | 2 |
| Hardy, E; Jabbour, SA; Parikh, S; Sugg, J | 1 |
| Arndt, E; Deacon, CF; Holst, JJ; Nauck, MA; Vardarli, I | 1 |
| Berk, A; Broedl, UC; Ferrannini, E; Hach, T; Hantel, S; Pinnetti, S; Woerle, HJ | 1 |
| Li, H; Lu, J; Zang, J | 1 |
| Fujita, H; Hayashi, H; Kikuchi, N; Komatsu, K; Komatsu, T; Murayama, H; Narita, T; Ohshiro, H; Sato, S; Taniai, H; Yamada, Y | 1 |
| Huh, W; Jung, JA; Kaku, K; Kim, JH; Kim, JR; Ko, JW; Lee, SY | 1 |
| Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR | 1 |
| Aulinger, BA; Bedorf, A; de Heer, J; Göke, B; Holst, JJ; Kutscherauer, G; Schirra, J | 1 |
| Diamant, M; Heymans, MW; Mari, A; Muskiet, MH; Ouwens, DM; Pouwels, PJ; van Genugten, RE; van Raalte, DH | 1 |
| Scheen, AJ; Van Gaal, LF | 3 |
| Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J | 1 |
| Sakr, HF | 1 |
| Anz, D; Bourquin, C; Endres, S; Haubner, S; Kruger, S; Rapp, M | 1 |
| Gahler, RJ; Grover, GJ; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S | 1 |
| Plosker, GL | 1 |
| Cunningham, C; Dey, M; Forest, T; Frederick, C; Holder, D; Prahalada, S; Smith, A; Yao, X | 1 |
| Hanaoka, H; Hashimoto, N; Ishikawa, K; Kanatsuka, A; Kobayashi, K; Kuribayashi, N; Onishi, S; Sakurai, K; Sato, Y; Takemoto, M; Terano, T; Uchida, D; Yokoh, H; Yokote, K | 1 |
| Deng, H; Ji, A; Yin, J | 1 |
| Schnell, O | 1 |
| da Silva, Fde C; Ferreira, VF; Gonzaga, D; Senger, MR; Silva, FP | 1 |
| Abe, J; Hara, H; Kinosada, Y; Nagasawa, H; Nakamura, M; Nishibata, Y; Suzuki, Y; Umetsu, R | 1 |
| Bond, SJ; Dutka, DP; Hoole, SP; Kydd, AC; McCormick, LM; Read, PA; Ring, LS | 1 |
| Davies, MJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Round, EM | 1 |
| Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF | 1 |
| Amemiya, H; Honda, S; Hoshino, K; Iemitsu, K; Iizuka, T; Ishikawa, M; Iwasaki, T; Kanamori, A; Kaneshige, H; Kaneshiro, M; Kawata, T; Kubota, A; Machimura, H; Maeda, H; Matoba, K; Matsuba, I; Minagawa, F; Minami, N; Miyairi, Y; Miyakawa, M; Mokubo, A; Motomiya, T; Naka, Y; Nakajima, S; Obana, M; Saito, T; Sasai, N; Takai, M; Takeda, H; Takuma, T; Tanaka, K; Tanaka, Y; Terauchi, Y; Tsurui, N; Uehara, G; Umezawa, S; Waseda, M | 1 |
| Arai, K; Hirao, K; Hirao, S; Hirao, T; Kumakura, A; Maeda, H; Shirabe, S; Yamamoto, R; Yamauchi, M | 1 |
| Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
| Hirata, T; Inukai, K; Ishida, H; Katayama, S; Morimoto, J | 1 |
| Tibaldi, JM | 1 |
| Fuchigami, M; Goda, T; Imai, C; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Ferrannini, E; Mari, A; Polidori, D | 1 |
| Napoli, N | 1 |
| Coric, J; Dizdarevic-Bostandzic, A; Djelilovic-Vranic, J; Izetbegovic, S; Karamehic, J; Macic-Dzankovic, A; Panjeta, M; Velija-Asimi, Z | 1 |
| Dong, S; Jia, J; Mao, C; Qian, W; Tang, B; Wang, D; Yang, L; Ye, J; Yu, S; Yuan, G; Zhang, C; Zhou, L; Zhu, T | 1 |
| Broedl, UC; Delafont, B; Eilbracht, J; Kim, G; Roden, M; Weng, J; Woerle, HJ | 1 |
| Borders-Hemphill, V; Hampp, C; Moeny, DG; Wysowski, DK | 1 |
| Bound, MJ; Checklin, H; Deacon, CF; Horowitz, M; Jones, KL; Ma, J; Rayner, CK; Wu, T | 1 |
| Fukumoto, M; Hiura, Y; Hosoi, M; Ikuno, Y; Kawasaki, I; Okada, M; Tamai, A; Tanaka, N; Ueno, H; Yakusiji, Y; Yamagami, K; Yoshida, Y | 1 |
| Johnson, JL; Kim, MK; O'Neal, KS; Pack, CC | 1 |
| Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ | 1 |
| Bailey, CJ; Diamant, M; Fouqueray, P; Inzucchi, SE; Lebovitz, HE; Pirags, V; Schernthaner, G | 1 |
| Komatsu, M; Miya, K; Noma, Y; Shima, K | 1 |
| Guerci, B; Milicevic, Z; Nauck, M; Skrivanek, Z; Umpierrez, GE; Weinstock, RS | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Bando, YK; Ishizu, T; Kodama, K; Murohara, T; Node, K; Oyama, J; Sato, Y | 1 |
| Garg, K; Kumar, S; Tripathi, CD | 1 |
| Agoramoorthy, G; Chakraborty, C; Hsu, MJ | 1 |
| Fernandes, R; Fontes-Ribeiro, C; Gonçalves, A; Marques, C; Mega, C; Reis, F; Rodrigues-Santos, P; Teixeira, F; Teixeira-Lemos, E | 1 |
| Nandith, A; Ramachandran, A; Shetty, AS; Snehalath, C | 1 |
| Ishida, H; Osonoi, T; Osonoi, Y; Saito, M; Tamasawa, A | 1 |
| Funahashi, T; Hayashi, M; Hibuse, T; Hirata, A; Kashine, S; Kimura, T; Kishida, K; Maeda, N; Minami, T; Nakagawa, Y; Nishizawa, H; Oka, A; Shimomura, I; Takeshita, E | 1 |
| Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F | 1 |
| Guthrie, R; Slee, A; Traina, S | 1 |
| Chen, TY; Hsieh, CJ | 1 |
| Inden, Y; Ishii, H; Ishikawa, S; Koyasu, M; Murohara, T; Shimano, M; Takemoto, K; Uchikawa, T; Watarai, M | 1 |
| Barros, JI; Cunha, GH; d'Alva, CB; Fechine, FV; Fernandes, VO; Montenegro Júnior, RM; Moraes, ME; Moraes, MO; Souza, MH; Vale, OC | 1 |
| Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M | 1 |
| Persson, U; Steen Carlsson, K | 1 |
| Katoh, N; Nakai, N | 1 |
| Fuller, CS; Gallop, R; Gudipaty, L; Rickels, MR; Rosenfeld, NK; Schutta, MH | 1 |
| Eurich, DT; McAlister, FA; Minhas-Sandhu, JK; Senthilselvan, A; Weir, DL | 1 |
| Bhatt, DL; Cavender, MA | 1 |
| Doggrell, SA; Tuli, R | 1 |
| Jin, D; Sakonjo, H; Takai, S | 1 |
| Couture, P; Deacon, CF; Lamarche, B; Tremblay, AJ; Weisnagel, SJ | 2 |
| Baldi, S; Casolaro, A; Cobb, J; Ferrannini, E; Frascerra, S; Gall, W; Mari, A; Muscelli, E | 1 |
| Carr, MC; Handelsman, Y; Jones-Leone, A; Leiter, LA; Scott, R; Stewart, M; Yang, F | 1 |
| Charest, A; Couture, P; Droit, A; Kelly, I; Lamarche, B; Lépine, MC; Tremblay, AJ | 1 |
| Fukuda, S; Hirata, K; Ito, H; Kihara, H; Miyoshi, T; Nakamura, K; Oe, H; Shimada, K; Takagi, T; Watanabe, K; Yoshikawa, J; Yunoki, K | 1 |
| Gou, Z; Ma, M; Wang, F; Wang, T; Zhai, SD | 1 |
| Ban, N; Kawana, H; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Saiki, A; Shirai, K; Tatsuno, I; Yamaguchi, T | 1 |
| Inoue, T; Kyou, C; Morishita, K; Ogawa, T; Taguchi, Y; Umayahara, R; Yonemoto, T | 1 |
| Asai, S; Kato, H; Kondo, A; Nagai, Y; Ohta, A; Sada, Y; Sasaoka, T; Tanaka, Y | 1 |
| Aaboe, K; Akram, S; Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Kourlaba, G; Maniadakis, N; Melidonis, A; Tzanetakos, C; Verras, C | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Ametov, AS; Gusenbekova, DG | 1 |
| Ando, K; Nishimura, R; Sakamoto, M; Seo, C; Tsujino, D; Utsunomiya, K | 1 |
| Jabbour, S | 1 |
| Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G | 1 |
| Hong, D; Wu, B; Xiao, Y; Zhao, Q; Zheng, D | 1 |
| Hsieh, CJ; Shen, FC | 1 |
| Horikawa, Y; Mikada, A; Narita, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H | 1 |
| Chopra, BS; Choudhary, V; Garg, R; Garg, V; Khatri, N; Peddada, N; Sagar, A | 1 |
| Akay, A; Dragomir, A; Erlandsson, BE | 1 |
| Doggrell, S | 1 |
| Thompson, AM; Trujillo, JM | 1 |
| Kabbara, WK; Ramadan, WH | 1 |
| Cornell, S | 1 |
| Bailey, RA; Blonde, L; Meininger, GE; Rupnow, MF; Vijapurkar, U | 1 |
| Avram, S; Borcan, F; Buiu, C; Duda-Seiman, C; Duda-Seiman, D; Milac, AL; Pacureanu, L | 1 |
| Cataño-Cañizalez, YG; Cortés-Garcia, JD; Cortez-Espinosa, N; Guzman-Flores, JM; Portales-Perez, DP; Rodríguez-Rivera, JG; Vargas-Morales, JM | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Rupnow, MF; Vijapurkar, U | 1 |
| Baek, JH; Huh, WS; Jin, SM; Jung, JA; Kaku, K; Kim, JH; Kim, JR; Kim, MJ; Ko, JW; Lee, SY | 1 |
| Armstrong, PW; Bethel, MA; Buse, JB; Engel, SS; Garg, J; Green, JB; Holman, RR; Josse, R; Kaufman, KD; Koglin, J; Korn, S; Lachin, JM; McGuire, DK; Pencina, MJ; Peterson, ED; Standl, E; Stein, PP; Suryawanshi, S; Van de Werf, F | 1 |
| Chen, DY; Chen, TH; Cherng, WJ; Chou, CC; Hsieh, IC; Hung, KC; Lin, YS; Mao, CT; Su, FC; Tsai, ML; Wang, CC; Wang, SH; Wen, MS | 1 |
| Markun, S | 1 |
| Zechmann, S | 1 |
| Holman, RR; Peterson, ED | 1 |
| Ashcroft, DM; Rutter, MK; Wright, AK | 1 |
| Kumar, HK | 1 |
| Kay, GN | 1 |
| Dimmitt, SB; Doggrell, SA | 1 |
| Abdul Razak, AR; Bartha-Vári, JH; Boros, Z; Cai, S; Carlson, R; Chong, YS; Chua, SY; Dagis, A; Feng, X; Foo, VH; Gabrail, NY; Gerecitano, JF; Gluckman, P; Huber, S; Ikram, MK; Irimie, FD; Kauffman, M; Kim, R; Kwek, K; Landesman, Y; Lassen, U; Li, D; Li, Q; Liu, C; Ma, J; Mahipal, A; Mau-Soerensen, M; McCauley, D; Mirza, MR; Nademanee, A; Ngo, C; Paizs, C; Palmer, JM; Pizzari, T; Poppe, L; Rashal, T; Saint-Martin, JR; Saw, SM; Shacham, S; Shields, AF; Stayner, LA; Tan, CS; Thorborg, K; Toşa, MI; Tsai, NC; Unger, TJ; Verkicharla, PK; Vértessy, BG; Wang, S; Wang, Y; Weiser, D; Wollin, M; Wong, TY; Xu, L; Yuan, L; Yuan, S; Zhang, Y; Zheng, R | 1 |
| Huang, W; Li, H; Li, Z; Liu, C; Qian, H; Wang, N; Wang, X; Yang, J | 1 |
| Ishii, Y; Ito, H; Kon, K; Sakurai, T; Sasahara, M; Sasaoka, T; Takahara, S; Toyooka, N; Tsuneki, H; Wada, T; Yamazaki, M; Yanagisawa, M | 1 |
| Han, L; Li, Q; Zhang, B; Zhang, H; Zhou, J | 1 |
| Bell, S; Calder, GL; Lee, MH; MacIsaac, RJ; Sachithanandan, N; Zeimer, H | 1 |
| Bhadada, SV; Ghate, MD; Patel, BD | 1 |
| Bailey, CJ; Flatt, PR; Green, BD | 3 |
| Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H | 1 |
| Arellano, S; Di Girolamo, G; Gagliardino, JJ; Santoro, S | 1 |
| Amatruda, JM; Arjona Ferreira, JC; Chan, JC; Davies, MJ; Gonzalez, E; Kaufman, KD; Scott, R; Sheng, D; Stein, PP; Williams-Herman, D | 1 |
| Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Ahrén, B | 5 |
| Elisaf, MS; Florentin, M; Liberopoulos, EN; Mikhailidis, DP | 1 |
| Pei, Z | 1 |
| Gadsby, R | 1 |
| Doupis, J; Veves, A | 1 |
| Herman, G; Krishna, R; Wagner, JA | 1 |
| DeFronzo, RA; Guan, X; Holcombe, JH; MacConell, L; Okerson, T; Viswanathan, P | 1 |
| Campbell, RK; Neumiller, JJ; Reynolds, JK | 1 |
| Davidson, JA; Gross, JL; Parente, EB | 1 |
| Faust, M; Matthes, J | 1 |
| Fonseca, VA; John-Kalarickal, J; Wani, JH | 1 |
| Taéron, C | 1 |
| Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E | 1 |
| Feinglos, M; Green, J | 1 |
| Bandeira-Echtler, E; Bergerhoff, K; Lerch, C; Richter, B | 1 |
| Amatruda, JM; Kaufman, KD; Langdon, RB; Mohan, V; Noble, L; Son, HY; Stein, PP; Xu, L; Yang, W | 1 |
| Gupta, R; Pal, M; Parsa, KV; Singh, SK; Tokala, RK; Walunj, SS | 1 |
| Siddiqui, NI | 1 |
| Boye, KS; Fabunmi, R; Lage, MJ; Misurski, DA | 1 |
| Bergman, AJ; Davies, MJ; Dilzer, SC; Herman, GA; Lasseter, KC; Luo, WL; Migoya, EM; Stevens, CH; Wagner, JA | 1 |
| Amatruda, JM; Davies, MJ; Goldstein, BJ; Johnson, J; Kaufman, KD; Luo, E; Teng, R; Williams-Herman, D | 1 |
| Gallen, IW; Lumb, AN | 1 |
| Amatruda, JM; Fukao, Y; Johnson-Levonas, AO; Nonaka, K; Okuyama, K; Tsubouchi, H | 1 |
| Argyrakopoulou, G; Doupis, J | 1 |
| Nicolucci, A; Rossi, MC | 1 |
| Barile, E; Chen, LH; Chen, V; Dahl, R; De, SK; Emdadi, A; Machleidt, T; Murphy, R; Pellecchia, M; Riel-Mehan, M; Stebbins, JL; Yuan, H | 1 |
| Kripke, C | 1 |
| East, HE; Riche, DM; Riche, KD | 1 |
| Mikhail, N | 2 |
| Butler, AE; Butler, PC; Cox, HI; Dry, S; Galasso, R; Gurlo, T; Matveyenko, AV; Moshtaghian, A | 1 |
| Gallwitz, B | 6 |
| Arjona Ferreira, JC; Horie, Y; Kanazu, S; Narukawa, M; Nonaka, K; Takeuchi, M; Taniguchi, T | 1 |
| Keating, N | 1 |
| Alexander, CM; Chapell, R; Gould, AL | 1 |
| Giampietro, O; Matteucci, E | 1 |
| Alba, M; Goldstein, BJ; Guan, Y; Herman, G; Kaufman, KD; Larson, P; Sachs, JR; Sheng, D; Thornberry, N; Williams-Herman, D | 1 |
| Cross, LB; Gentry, C; Gross, B; McFarland, MS; Patel, UP; Tunney, J | 1 |
| Gallwitz, B; Thornberry, NA | 1 |
| Eiermann, GJ; Feng, Y; Howard, AD; Li, C; Li, Z; Mu, J; Petrov, A; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
| Curtiss, FR; Fairman, KA | 1 |
| Bode, BW | 1 |
| Matthaei, S | 1 |
| Bischoff, A | 1 |
| Barnett, AH; Palalau, AI; Piya, MK; Tahrani, AA | 1 |
| Freeman, JS | 2 |
| Henson, K; Hight, R; Welborn, D; Wyatt, S | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Alexander, CM; Siler, SQ; Topp, BG; Waters, SB | 1 |
| Hoerger, T; Pogach, L; Rajan, M; Sinha, A | 1 |
| Aschner, P; Goldstein, BJ; Guo, H; Katzeff, HL; Kaufman, KD; Sunga, S; Williams-Herman, D | 1 |
| Amatruda, JM; Andryuk, PJ; Cefalu, WT; Chen, Y; Engel, SS; Katz, L; Kaufman, KD; Ling, Y; Luo, E; Musser, B; Rosenstock, J; Vilsbøll, T; Yki-Järvinen, H | 1 |
| Cross, LB; Foard, J; Gross, BN; Wood, Y | 1 |
| Bilkovski, R; Faust, M; Freude, S; Krone, W; Laudes, M; Oberhauser, F; Schilbach, K; Schulte, DM; Schulz, O | 1 |
| Dhillon, S | 1 |
| Peters, A | 1 |
| Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S | 1 |
| Amatruda, J; Arjona Ferreira, JC; Iwamoto, Y; Nonaka, K; Okamoto, T; Okuyama, K; Taniguchi, T | 1 |
| Meier, JJ; Menge, BA; Schmidt, WE | 1 |
| Agostini, C; Albiero, M; Avogaro, A; Boscaro, E; de Kreutzenberg, S; Fadini, GP; Frison, V; Menegazzo, L; Tiengo, A | 1 |
| Bilan, VP; Jackson, EK; Tofovic, DS | 1 |
| Aaboe, K; Deacon, CF; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T | 1 |
| Cefalu, WT | 1 |
| Butler, C; Clarke, P; Habibi, M; Howard, D; Kulendra, K | 1 |
| Clay, RJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Machotka, SV; Williams-Herman, DE | 1 |
| Amatruda, JM; Goldstein, BJ; Golm, G; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D | 1 |
| Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Montanya, E; Nauck, M; Pratley, RE; Søndergaard, RE; Thomsen, AB | 1 |
| Amatruda, JM; Davies, MJ; Kaufman, KD; Nauck, M; Seck, T; Sheng, D; Stein, PP; Sunga, S | 1 |
| Berria, R; Davis, KL; Horton, ES; Silberman, C | 1 |
| Davies, MJ; Engel, SS; Mavros, P; Radican, L; Rajagopalan, S; Yin, D; Zhang, Q | 2 |
| Guerci, B; Halter, C | 1 |
| Abel, T; Fehér, J | 1 |
| Aoki, K; Masuda, K; Miyazaki, T; Terauchi, Y; Togashi, Y | 1 |
| Garg, R; Hussey, C; Ibrahim, S | 1 |
| Baudrant, M; Benhamou, PY; Halimi, S; Lablanche, S; Skalli, S; Wion-Barbot, N | 1 |
| Unger, J | 1 |
| Kuritzky, L | 1 |
| Meier, JJ; Nauck, MA | 1 |
| Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P | 1 |
| Amatruda, JM; Arjona Ferreira, JC; Iwamoto, Y; Kadowaki, T; Nishii, M; Nonaka, K; Tajima, N; Taniguchi, T | 1 |
| Fakhoury, WK; Lereun, C; Wright, D | 1 |
| Brinker, A; Desai, S; Iyasu, S; Swann, J | 1 |
| Svec, F | 1 |
| Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N | 1 |
| Fernandes, R; Ferreira, L; Garrido, P; Mega, C; Melo, A; Nunes, S; Parada, B; Pinto, F; Pinto, R; Reis, F; Santos, P; Sereno, J; Teixeira, F; Teixeira-de-Lemos, E; Vala, H; Velada, I | 1 |
| Jackson, EK | 1 |
| Brown, NJ; Byrne, L; Kunchakarra, S; Marney, A | 1 |
| Chen, W; Garg, R; Pendergrass, M | 1 |
| Gerich, J | 1 |
| Bhalodia, Y; Manek, R; Sheth, N; Vaghasiya, J | 1 |
| Garber, AJ | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
| Charpentier, G; Gause-Nilsson, I; Hellqvist, A; Ostgren, CJ; Scheen, AJ | 1 |
| Opsteen, C; Qi, Y; Retnakaran, R; Vivero, E; Zinman, B | 1 |
| Alexander, CM; Cai, B; Girman, CJ; Katz, L; Williams-Herman, D | 1 |
| Caputo, S; Ghirlanda, G; Martini, F; Musella, T; Pitocco, D; Scavone, G; Zaccardi, F | 1 |
| Carpentier, AC; Croteau, E; Frisch, F; Grenier-Larouche, T; Guérin, B; Labbé, SM; Normand-Lauzière, F; Ouellet, R; Turcotte, EE | 1 |
| Anjana, RM; Kishore, U; Mohan, V; Sudhakaran, C; Unnikrishnan, R | 1 |
| Arechavaleta, R; Chen, Y; Duran, L; Goldstein, BJ; Kaufman, KD; Krobot, KJ; O'Neill, EA; Seck, T; Williams-Herman, D | 1 |
| Hollander, P; Liutkus, JF; Raslova, K; Råstam, J; Skjøth, TV | 1 |
| Hattori, S | 1 |
| Amatruda, JM; Golm, GT; Kaufman, KD; Meehan, AG; Shockey, GR; Steinberg, H; Teng, R; Thakkar, PR; Williams-Herman, DE; Yoon, KH | 1 |
| Acuña, C | 1 |
| Boudes, P; Viereck, C | 1 |
| Best, JH; Garrison, LP; Li, Y; Malloy, J; Peyrot, M; Rubin, RR; Yan, P | 1 |
| Desai, AA | 1 |
| Bergman, AJ; Chen, L; Davies, MJ; Gottesdiener, KM; Herman, GA; Langdon, RB; Larson, PJ; Mistry, GC; Ruckle, JL; Snyder, K; Wagner, JA; Wang, AQ; Yi, B; Zeng, W | 1 |
| Seyoum, B | 1 |
| Chang, FY; Ho, SJ; Lin, JC; Shang, ST; Wang, NC; Yang, YS | 1 |
| Jellinger, PS | 1 |
| Ishiki, M; Ito, S; Mori, T; Nako, K; Ogawa, S; Okamura, M; Senda, M | 1 |
| Cuddihy, R; Davies, M; Hammer, M; Pratley, R; Thomsen, AB | 1 |
| Chwieduk, CM | 1 |
| Butler, PC; Elashoff, M; Elashoff, R; Gier, B; Matveyenko, AV | 1 |
| Chen, B; Ernsberger, P; Escobedo, LV; Hou, D; Koletsky, MS; Koletsky, RJ; Moore, A | 1 |
| Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Garber, A; Hartvig, H; Montanya, E; Nauck, M; Pratley, R; Thomsen, AB | 1 |
| Spellman, CW | 1 |
| Chen, M; Goldstein, BJ; Johnson-Levonas, AO; Kaufman, KD; Olansky, L; Reasner, C; Seck, TL; Terranella, L; Williams-Herman, DE | 1 |
| Amatruda, JM; Barzilai, N; Caporossi, S; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Langdon, RB; Mahoney, EM; Steinberg, H; Williams-Herman, D | 1 |
| Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Daniela, L; Ludvik, B | 1 |
| Charavgi, MD; Chrysina, ED; Czecze, L; Docsa, T; Gergely, P; Kun, S; Nagy, GZ; Patonay, T; Skourti, PV; Somsák, L; Tóth, M; Van Nhien, AN | 1 |
| Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Seck, TL; Sisk, CM; Wang, H; Williams-Herman, DE | 1 |
| Hawkes, N | 1 |
| Matsuura, K; Mori, Y; Sezaki, K; Taniguchi, Y; Utsunomiya, K; Yokoyama, J | 1 |
| Hibi, T; Kaneko, F; Motoori, T; Oda, M; Ohbu, M; Shimizu, Y; Tahara, K; Takeuchi, H; Toyoda-Akui, M; Yokomori, H | 1 |
| Doggrell, SA | 1 |
| Chen, M; Goldstein, BJ; Kaufman, KD; Mehta, A; Olansky, L; Reasner, C; Seck, TL; Terranella, L; Williams-Herman, DE | 1 |
| Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R | 1 |
| Chisholm, DJ; Douglas, A; Greenfield, JR; Gribble, FM; Holst, JJ; Piyaratna, N; Samocha-Bonet, D; Synnott, EL; Wong, O | 1 |
| Kondo, M; Tanizawa, Y | 1 |
| Berg, JK; Gray, AL; Heilmann, CR; Holcombe, JH; Shenouda, SK | 1 |
| Hibi, H; Ohori, T; Yamada, Y | 1 |
| Kipnes, M; Subbarayan, S | 1 |
| Elahi, D; Meneilly, GS; Stafford, S | 1 |
| Khera, S; Rustagi, T; Uy, EM | 1 |
| Gundert-Remy, U; Spranger, J; Stammschulte, T | 1 |
| Hurren, KM; Pinelli, NR | 1 |
| DeYoung, MB; Herbert, P; MacConell, L; Sarin, V; Trautmann, M | 1 |
| Fan, L; Gruenberger, JB; Kantor, E; Signorovitch, JE; Swallow, E; Wu, EQ | 1 |
| Engel, SS; Goldstein, BJ; Kaufman, KD; Lee, MA; Pérez-Monteverde, A; Seck, T; Sisk, CM; Williams-Herman, DE; Xu, L | 1 |
| Cander, S; Ersoy, C; Ertürk, E; Gül, CB; Imamoğlu, S; Kırhan, E; Kıyıcı, S; Öz, Ö; Sarandol, E; Sığırlı, D; Tuncel, E; Ünal, OK; Yorulmaz, H | 1 |
| Chubb, BD; Davies, MJ; Smith, IC; Valentine, WJ | 1 |
| Jermendy, G | 2 |
| Aoki, K; Kamiyama, H; Masuda, K; Shibuya, M; Terauchi, Y; Yoshimura, K | 1 |
| Akehi, Y; Kobayashi, K; Kodera, T; Kudo, T; Nagaishi, R; Nagasako, H; Nomiyama, T; Takenoshita, H; Terawaki, Y; Urata, H; Yanase, T | 1 |
| Al Elq, A; Al Omari, M; Al Sifri, S; Al Tayeb, K; Basiounny, A; Davies, MJ; Echtay, A; Engel, SS; Girman, CJ; Harman-Boehm, I; Kaddaha, G; Katzeff, HL; Mahfouz, AS; Musser, BJ; Ozesen, C; Radican, L; Suryawanshi, S | 1 |
| Ahn, HY; An, JH; Cho, YM; Choi, SH; Jang, HC; Kang, SM; Khang, AR; Lee, Y; Lim, S; Park, KS; Shin, H; Yoon, JW | 1 |
| Ogawa, Y; Shimada, S; Tanaka, K | 1 |
| Niessen, M; Spinas, GA; Xu, L | 1 |
| Davies, MJ; Goldstein, BJ; Golm, GT; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D; Xu, L | 1 |
| Kubota, A; Maeda, H; Matsuba, I; Tanaka, Y; Terauchi, Y | 1 |
| Hashimoto, K; Kumagai, C; Nishioka, T; Shinohara, M; Tanimoto, N | 1 |
| Engel, SS; Goldstein, BJ; Golm, GT; Hussain, S; Katz, L; Kaufman, KD; O'Neill, EA; Wainstein, J; Xu, L | 1 |
| Gerrald, KR; Jonas, DE; Runge, T; Van Scoyoc, E; Wines, RC | 1 |
| Aso, Y; Hara, K; Haruki, K; Inukai, T; Morita, K; Naruse, R; Ozeki, N; Shibazaki, M; Suetsugu, M; Takebayashi, K; Terasawa, T | 1 |
| Kato, T; Kono, S; Ohki, T; Sasaki, Y; Tajiri, Y; Tanaka, K; Tojikubo, M; Tsuruta, M; Yamada, K | 1 |
| Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B | 1 |
| Masmiquel Comas, L; Nicolau Ramis, J | 1 |
| Kishimoto, M; Noda, M | 1 |
| Koshy, R; Malhotra, P | 1 |
| de Lemos, ET; Fernandes, R; Mascarenhas-Melo, F; Mega, C; Oliveira, J; Reis, F; Teixeira, F; Vala, H | 1 |
| Boardman, MK; Chan, M; Cuddihy, RM; González, JG; Hanefeld, M; Kumar, A; Russell-Jones, D; Wolka, AM | 1 |
| Huh, JW; Jang, M; Kim, DH; Kim, TW; Park, JS; Suh, JH; Yoon, SY | 1 |
| Chen, W; Fenton, C; Haffner, SM; Pendergrass, M | 1 |
| Briand, F; Burcelin, R; Sulpice, T; Thieblemont, Q | 1 |
| Furukawa, S; Kumagi, T; Matsuura, B; Miyake, T; Murakami, M; Murakami, S; Niiya, T; Nishino, K; Onji, M; Ueda, T | 1 |
| Holst, JJ; Liu, MK; Salen, G; Saumoy, M; Shang, Q; Xu, G | 1 |
| Campos-Herrero, MI; Horcajada, I; Medina-Rivero, F; Tandón, L | 1 |
| Caminal-Montero, L; Coto-Segura, P; Esteve-Martinez, A; Mas-Vidal, A; Santos-Juanes, J | 1 |
| Gambale, JJ; Katz, LB; Rothenberg, PL; Sarich, TC; Stein, PP; Vaccaro, N; Vanapalli, SR; Xi, L | 1 |
| Best, JH; DeYoung, MB; Gaebler, JA; Guillermin, AL; Lloyd, A; Samyshkin, Y | 1 |
| Bachmann, OP; Chan, JY; Lüdemann, J; Oliveira, JH; Reed, VA; Violante, R; Yoon, KH; Yu, MB | 1 |
| Boddu, ND; Cheskin, LJ; Kahan, S; Kumar, AA; Palamaner Subash Shantha, G; Samson, RJ | 1 |
| Hood, AF; Litt, JZ; Rader, RK; Schuman, TP; Stoecker, WV; Stricklin, SM | 1 |
| Nauck, MA | 1 |
| Goldstein, BJ; Golm, GT; Kaufman, KD; Lee, M; O'Neill, EA; Steinberg, H; Teng, R; Yoon, KH | 1 |
| Davies, M; Speight, J | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Rabasseda, X | 1 |
| Choi, SH; Hong, ES; Jang, HC; Kang, SM; Khang, AR; Lim, S; Park, KS; Shin, H; Walford, GA; Yoon, JW | 1 |
| Ahrén, B; Deacon, CF; Mannucci, E | 1 |
| Berman, S; Efrati, S; Golik, A; Hamad, RA; Koren, S; Peleg, RK; Shemesh-Bar, L; Tirosh, A; Vinker, S | 1 |
| Aono, M; Fukushima, T; Harashima, SI; Inagaki, N; Koizumi, T; Murata, Y; Ogura, M; Seike, M; Tanaka, D; Wang, Y | 1 |
| Lam, SY; Leung, KK; Leung, PS; Liang, J | 1 |
| Capuano, G; Nicolle, LE; Usiskin, K; Ways, K | 1 |
| Cheetham, S; Francis, J; Kirby, M; Poucher, SM; Vickers, SP; Zinker, B | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W | 1 |
| Fukuda, K; Itoh, H; Kawai, T; Matsuhashi, T; Meguro, S; Mogi, S; Sano, M; Suzuki, Y | 1 |
| Nyirjesy, P; Usiskin, K; Ways, K; Zhao, Y | 1 |
| Edgerton, LP; Elmore, LK; Patel, MB; Whalin, LM | 1 |
| Burgmaier, M; Esser, M; Liberman, A; Ludwig, A; Marx, N; Ostertag, R; Vasic, D; Vittone, F; Walcher, D | 1 |
| Alba, M; Engel, SS; Goldstein, BJ; Guan, Y; Johnson-Levonas, AO; Kaufman, KD; Li, Z; Shentu, Y; Yang, W | 1 |
| Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D | 1 |
| Aschner, P; Chan, J; Dain, MP; Echtay, A; Fonseca, V; Owens, DR; Picard, S; Pilorget, V; Wang, E | 1 |
| Diamant, M | 1 |
| Firneisz, G; Somogyi, A | 1 |
| Alba, M; Astiarraga, B; Casolaro, A; Chen, Y; Ferrannini, E; Gastaldelli, A; Holst, J; Mari, A; Muscelli, E; Seghieri, G | 1 |
| Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR | 2 |
| Davies, MJ; Ferrante, SA; Goldstein, BJ; Kaufman, KD; Krobot, KJ; Meininger, GE; Seck, T; Williams-Herman, D | 1 |
| Aso, Y | 1 |
| Aravind, SR; Balamurugan, R; Davies, MJ; Engel, SS; Girman, CJ; Gupta, JB; Ismail, SB; Katzeff, HL; Loh, SM; Radican, L; Suryawanshi, S; Wadhwa, T; Wolthers, T | 1 |
| Amatruda, JM; Aschner, P; Chen, Y; Dobs, AS; Duran, L; Ferreira, JC; Goldstein, BJ; Golm, GT; Hill, JS; Horton, ES; Kaufman, KD; Langdon, RB; Umpierrez, GE; Williams-Herman, DE | 1 |
| Abuaysheh, S; Chaudhuri, A; Dandona, P; Dhindsa, S; Ghanim, H; Green, K; Makdissi, A; Vora, M | 1 |
| Ferreira, SB; Ferreira, VF; Gomes, Lda C; Kaiser, CR; Senger, MR; Silva, FP | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D | 1 |
| Gupta, R; Keshwani, P; Saxena, GN; Srivastava, S | 1 |
| Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P | 1 |
| Langer, J; Lee, WC; Palmer, JL; Samyshkin, Y | 1 |
| Kaneto, H; Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M | 1 |
| Bailey, T; Davies, M; Filetti, S; Furber, S; Garber, AJ; Montanya, E; Nauck, MA; Pratley, RE; Thomsen, AB | 1 |
| Buse, J; Jensen, KH; Niswender, K; Pi-Sunyer, X; Russell-Jones, D; Toft, AD; Zinman, B | 1 |
| Igaki, N; Yokota, K | 1 |
| Ando, K; Irako, T; Nishimura, R; Sakamoto, M; Tsujino, D; Utsunomiya, K | 1 |
| Vella, A | 1 |
| Celikel, CA; Deyneli, O; Duman, DG; Kalayci, C; Yilmaz, Y; Yonal, O | 1 |
| Gahler, RJ; Grover, GJ; Juneja, P; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S | 1 |
| Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H | 1 |
| Bajaj, M; Birnbaum, Y; Castillo, AC; Ling, S; Perez-Polo, JR; Qian, J; Ye, H; Ye, Y | 1 |
| Liu, XL; Lü, XF; Shao, C; Wang, P; Xiao, XH; Xu, ZR; Yang, WY; Yang, ZJ | 1 |
| Gupta, AK; Kailashiya, J; Kumar, N; Singh, SK; Verma, AK | 1 |
| Aono, M; Fujita, Y; Harashima, SI; Inagaki, N; Koizumi, T; Murata, Y; Ogura, M; Seike, M; Tanaka, D; Wang, Y; Yamane, S | 1 |
| Chen, M; Guo, Z; Hao, J; Houze, J; Lin, DC; Lopez, E; Luo, J; Ma, Z; Nguyen, K; Rulifson, IC; Tian, B; Tian, L; Tran, T; Wang, Y; Zhang, Y | 1 |
| Hansen, LS; Hare, KJ; Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS; Rosenkilde, MM; Viby, NE | 1 |
| Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K | 1 |
| Bianchi, L; Bonaventura, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D | 1 |
| Huisamen, B | 1 |
| Hasegawa, K; Iguchi, A; Kono, S; Nakagawachi, R; Odori, S; Sasaki, Y; Satoh-Asahara, N; Shimatsu, A; Tochiya, M; Wada, H | 1 |
| Drouet, C; Graffin, B; Hosotte, M; Kanny, G; Landy, C; Millot, I; Nadaud, J; Plancade, D; Ragot, C | 1 |
| Mateos, JL; Wajchenberg, BL | 1 |
| Ikeda, T; Kirinoki-Ichikawa, S; Kubota, Y; Miyamoto, M; Mizuno, K; Takagi, G; Tanaka, K | 1 |
| Mahé, E; Sigal, ML; Sin, C | 1 |
| Arjona Ferreira, JC; Barzilai, N; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Marre, M; Sisk, CM | 1 |
| Devries, JH | 1 |
| Inazumi, T; Kimura, M; Komatsu, Y; Kondo, Y; Nakamura, A; Tajima, K; Takihata, M; Tamura, H; Terauchi, Y; Yamada, M; Yamazaki, S | 1 |
| Davies, MJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Shapiro, D | 1 |
| Berry, D; Berry, S; Chien, J; Gaydos, B; Geiger, MJ; Skrivanek, Z | 1 |
| Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
| Brismar, K; Efendic, S; Hage, C; Lundman, P; Mellbin, L; Rydén, L | 1 |
| Arjona Ferreira, JC; Corry, D; Davies, MJ; Goldstein, BJ; Golm, GT; Gonzalez, EJ; Kaufman, KD; Mogensen, CE; Sloan, L; Xu, L | 1 |
| Bellon, M; Bound, MJ; Horowitz, M; Jones, KL; Rayner, CK; Standfield, SD; Wu, T; Zhao, BR | 1 |
| Baruah, MP; Chaudhury, T; Dharmalingam, M; Sethi, BK | 1 |
| Barbieri, M; Boccardi, V; Esposito, A; Marfella, R; Pansini, A; Paolisso, G; Rizzo, MR | 1 |
| Kanamori, A; Kubota, A; Maeda, H; Matsuba, I; Tanaka, Y; Terauchi, Y | 1 |
| Akiyama, E; Fujisue, K; Hokimoto, S; Iwashita, S; Jinnouchi, H; Kaikita, K; Kurokawa, H; Maeda, H; Matsubara, J; Ogawa, H; Ohba, K; Sugiyama, S; Yamamoto, E | 1 |
| Satoh, K | 1 |
| Ida, K; Ikeda, H; Katsuno, T; Miyagawa, J; Namba, M | 1 |
| Fujiwara, C; Furusawa, Y; Hagaya, M; Kakuta, H; Kawata, K; Kobayashi, T; Kohara, K; Makishima, M; Naitou, H; Nakayama, M; Ohsawa, F; Ohta, Y; Shinozaki, R; Tai, A; Yakushiji, N; Yamada, S; Yasui, H; Yoshikawa, Y | 1 |
| Dow, CS; Falcioni, G; Gabbianelli, R; Swoboda, B; Vince, FP | 1 |
| Beconi, M; Eiermann, GJ; Fisher, MH; He, H; Hickey, GJ; Kim, D; Kowalchick, JE; Leiting, B; Lyons, K; Marsilio, F; McCann, ME; Patel, RA; Patel, SB; Petrov, A; Roy, RS; Scapin, G; Thornberry, NA; Wang, L; Weber, AE; Wu, JK; Wyvratt, MJ; Zhang, BB; Zhu, L | 1 |
| Garbino, J; Lew, D; Rohner, P; Uckay, I; Van Delden, C | 1 |
| Bergman, AJ; Chen, L; Davies, MJ; De Smet, M; Herman, GA; Hilliard, D; Laethem, M; Ramael, S; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Wagner, JA; Wang, AQ; Winchell, G; Yi, B; Zeng, W; Zhou, Y | 1 |
| Heinzl, S | 1 |
| Feng, Y; Howard, AD; Li, C; Li, Z; Moller, DE; Mu, J; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
| Beconi, M; Di Salvo, J; Edmondson, SD; Eiermann, GJ; Harper, B; He, H; He, J; Leiting, B; Leone, JF; Levorse, DA; Lyons, K; Mastracchio, A; Mathvink, RJ; Park, YJ; Patel, RA; Patel, SB; Petrov, A; Roy, RS; Scapin, G; Shang, J; Smith, A; Thornberry, NA; Weber, AE; Wu, JK; Xu, S; Zhu, B | 1 |
| Bergman, A; Cilissen, C; Davies, MJ; de Lepeleire, I; De Smet, M; Deacon, CF; Dietrich, B; Golor, G; Gottesdiener, KM; Herman, GA; Hilliard, D; Holst, JJ; Keymeulen, B; Kipnes, MS; Kotey, P; Lasseter, KC; Schrodter, A; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Van Dyck, K; Wagner, JA; Wang, AQ; Yi, B; Zeng, W; Zhao, P | 1 |
| Warpakowski, A | 1 |
| Caria, C; Hanefeld, M; Khatami, H; Raz, I; Williams-Herman, D; Xu, L | 1 |
| Bergman, A; Herman, GA; Kipnes, M; Yi, B | 1 |
| Biftu, T; Eiermann, G; Feng, D; Gao, YD; He, H; Kieczykowski, G; Leiting, B; Liang, GB; Lyons, K; Patel, S; Petrov, A; Qian, X; Scapin, G; Singh, S; Sinha-Roy, R; Thornberry, NA; Weber, AE; Wu, J; Zhang, B; Zhang, X | 1 |
| Backes, BJ; Ballaron, SJ; Beno, DW; Fryer, RM; Judd, AS; Kempf-Grote, AJ; Li, X; Longenecker, K; Lubben, TH; Madar, DJ; Mika, AK; Mulhern, M; Pei, Z; Preusser, LC; Reinhart, GA; Sham, HL; Stashko, MA; Stewart, KD; Trevillyan, JM; von Geldern, TW; Yong, H; Zinker, BA | 1 |
| Barnett, A | 1 |
| Drucker, DJ; Nauck, MA | 1 |
| Traynor, K | 1 |
| Aschner, P; Kipnes, MS; Lunceford, JK; Mickel, C; Sanchez, M; Williams-Herman, DE | 1 |
| Charbonnel, B; Karasik, A; Liu, J; Meininger, G; Wu, M | 1 |
| Sanchez, M; Scott, R; Stein, P; Wu, M | 1 |
| Andryuk, PJ; Brazg, R; Lu, K; Rosenstock, J; Stein, P | 1 |
| Jackson, C | 1 |
| Nathan, DM | 1 |
| Brazg, R; Cobelli, C; Dalla Man, C; Stein, PP; Thomas, K; Xu, L | 1 |
| Meininger, G; Nauck, MA; Sheng, D; Stein, PP; Terranella, L | 1 |
| Drucker, D; Easley, C; Kirkpatrick, P | 1 |
| Campbell, KM; Taylor, JR | 1 |
| Lyseng-Williamson, KA | 1 |
| Kipnes, MS | 1 |
| Raz, I | 1 |
| Thornberry, NA; Weber, AE | 1 |
| Deacon, CF | 1 |
| Winkler, G | 1 |
| Sellart-Altisent, M; Torres-Rodríguez, JM | 1 |
| Herman, GA; Stein, PP; Thornberry, NA; Wagner, JA | 1 |
| Pratley, RE; Salsali, A | 1 |
| Bergman, AJ; Cote, J; Gottesdiener, K; Herman, GA; Marbury, T; Smith, W; Swan, SK; Wagner, J; Yi, B | 1 |
| Harada, AS; Lau, W | 1 |
| Feinglos, MN; Goldstein, BJ; Johnson, J; Lunceford, JK; Williams-Herman, DE | 1 |
| Bloomgarden, ZT; Inzucchi, SE | 1 |
| Mintz, ML | 1 |
| Irony, I; Meyer, RJ; Parks, MH | 1 |
| Eldor, R; Raz, I | 1 |
| Klein, HH; Meier, JJ; Schmidt, WE | 1 |
| Hanefeld, M; Herman, GA; Mickel, C; Sanchez, M; Stein, PP; Wu, M | 1 |
| Fanurik, D; Hermansen, K; Khatami, H; Kipnes, M; Luo, E; Stein, P | 1 |
| Amori, RE; Lau, J; Pittas, AG | 1 |
| Jennings, HR; Langley, AK; Suffoletta, TJ | 1 |
| Whitehill, D | 1 |
| Mirza, SA | 1 |
| Dailey, GE | 1 |
| Heinzl, S; Musch, A | 1 |
| Ahmed, T; Davies, MJ; Fujimoto, G; Hirayama, Y; Kakikawa, T; Kato, N; Nonaka, K; Okuyama, K; Sato, A; Stein, PP; Suzuki, H | 1 |
| Perusicová, J | 1 |
| Aschner, P; Davies, MJ; Karasik, A; Katzeff, H; Stein, PP | 1 |
| Alba, M; Amatruda, JM; Chen, Y; Hussain, S; Kaufman, KD; Langdon, RB; Raz, I; Stein, PP; Wu, M | 1 |
| Davies, MJ; Engel, SS; Loeys, T; Scott, R | 1 |
| Pyon, EY; Zerilli, T | 1 |
| Nogid, A; Pham, DQ; Plakogiannis, R | 1 |
| Bourolias, CA; Karatzanis, AD; Kofteridis, DP; Mantadakis, E; Papazoglou, G; Samonis, G; Velegrakis, GA | 1 |
| Bartberger, MD; Castro, VM; Chen, M; Emery, M; Fotsch, C; Gustafsson, S; Hale, C; Hickman, D; Homan, E; Johansson, L; Jordan, SR; Komorowski, R; Li, A; Matsumoto, G; McRae, K; Moniz, G; Orihuela, C; Palm, G; Veniant, M; Wang, M; Williams, M; Zhang, J | 1 |
| Bandeira-Echtler, E; Bergerhoff, K; Lerch, CL; Richter, B | 1 |
| Alemao, E; Chen, J; Cook, J; Gouveia, M; Jameson, K; Krishnarajah, G; Nocea, G; Schwarz, B; Sintonen, H; Yin, D | 1 |
| Charbonnel, B; Cobelli, C; Davies, MJ; Man, CD; Meninger, G; Stein, PP; Williams-Herman, D; Xu, L | 1 |
| Duh, D; Vandevijver, A | 1 |
| Erol, A | 1 |
| Choe, HM; Sweet, BV; VanDeKoppel, S | 1 |
| Biggs, F; Warnock, JK | 1 |
| Alderman, CP; Condon, JT; Gebauer, MG; Gilbert, AL | 1 |
129 review(s) available for triazoles and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Molecular Structure; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2013 |
Sitagliptin in the treatment of type 2 diabetes: a meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Topics: Adamantane; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular System; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Lipids; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2013 |
Fusarium falciforme infection of foot in a patient with type 2 diabetes mellitus: a case report and review of the literature.
Topics: Antifungal Agents; Biopsy, Fine-Needle; Diabetes Complications; Diabetes Mellitus, Type 2; Foot; Fusariosis; Fusarium; Humans; Male; Middle Aged; Pyrimidines; Triazoles; Voriconazole | 2013 |
Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis.
Topics: Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Pyrazines; Renal Insufficiency, Chronic; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2013 |
Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Metformin; Outcome Assessment, Health Care; Pioglitazone; Proinsulin; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult | 2014 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Clinical review of sitagliptin: a DPP-4 inhibitor.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Incretins; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Maculopapular-type drug eruption caused by sitagliptin phosphate hydrate: a case report and mini-review of the published work.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Eruptions; Female; Humans; Hypersensitivity, Delayed; Hypoglycemic Agents; Immunologic Tests; Lymphocyte Activation; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Skin; Triazoles; Withholding Treatment | 2014 |
Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Lipids; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2014 |
Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials.
Topics: Diabetes Mellitus, Type 2; Diarrhea; Humans; Hypoglycemic Agents; Odds Ratio; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Sitagliptin Phosphate; Triazoles | 2014 |
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2015 |
Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemia; Polypharmacy; Pyrazines; Risk Factors; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain | 2015 |
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2015 |
Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
Topics: Blood Pressure; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles | 2015 |
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
[New drugs; exenatide and sitagliptin].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2008 |
New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Peptide Fragments; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes.
Topics: Adult; Aged; Blood Pressure; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lipids; Male; Pregnancy; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Drugs for type 2 diabetes.
Topics: alpha-Galactosidase; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Piperidines; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Topics: Adamantane; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Nitriles; Protein Conformation; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Structure-Activity Relationship; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
New treatments for type 2 diabetes--the DPP4 inhibitors.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin | 2007 |
DPP4 inhibitors: a new approach in diabetes treatment.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes.
Topics: Animals; Biomarkers; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Janumet: a combination product suitable for use in patients with Type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles | 2008 |
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
[Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Incretin-based therapies in type 2 diabetes: a review of clinical results.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil | 2009 |
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Impact of sitagliptin on markers of beta-cell function: a meta-analysis.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Homeostasis; Humans; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Placebos; Proinsulin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2009 |
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
[The value of incretin based therapies].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.
Topics: Bayes Theorem; Confidence Intervals; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2009 |
Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.
Topics: Diabetes Mellitus, Type 2; Dimerization; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycosylation; Humans; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2009 |
Defining the importance of daily glycemic control and implications for type 2 diabetes management.
Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles | 2009 |
DPP-4 inhibitors in clinical practice.
Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Intracellular Signaling Peptides and Proteins; Peptides; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2010 |
Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Incretin-based therapies: review of current clinical trial data.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2010 |
[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Risk Factors; Satiety Response; Sitagliptin Phosphate; Triazoles; Weight Loss | 2010 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Pancreatitis; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Triazoles | 2010 |
[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
Topics: Administration, Oral; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2010 |
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss | 2010 |
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2010 |
Incretin physiology and its role in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin | 2010 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Sitagliptin and metformin--novel combination therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
The emerging life-threatening opportunistic fungal pathogen Kodamaea ohmeri: optimal treatment and literature review.
Topics: Aged; Antifungal Agents; Diabetes Mellitus, Type 2; Echinocandins; Female; Fungemia; Hematologic Neoplasms; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mycoses; Opportunistic Infections; Pyrimidines; Risk Factors; Saccharomycetales; Treatment Outcome; Triazoles; Voriconazole | 2010 |
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.
Topics: Algorithms; Chronic Disease; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Humans; Hypoglycemic Agents; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Sitagliptin: a review.
Topics: Administration, Oral; Algorithms; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
Topics: Adult; Blood Glucose; Capsules; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Lactic Acid; Peptides; Pioglitazone; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2011 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Treatment of primary aspergilloma of the central nervous system in a diabetic immunocompetent patient with surgical resection and voriconazole: a case report and review of the literature.
Topics: Aged; Antifungal Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Immunocompetence; Neuroaspergillosis; Neurosurgical Procedures; Pyrimidines; Temporal Lobe; Treatment Outcome; Triazoles; Voriconazole | 2011 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.
Topics: Aged, 80 and over; Biguanides; Blood Glucose; Depressive Disorder; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Overdose; Female; Glucose; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Suicide, Attempted; Sulfonylurea Compounds; Triazoles | 2012 |
Endophthalmitis caused by Phialophora verrucosa: a case report and literature review of Phialophora ocular infections.
Topics: Aged; Amphotericin B; Antifungal Agents; Caspofungin; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Resistance, Multiple, Fungal; Drug Therapy, Combination; Echinocandins; Endophthalmitis; Eye Enucleation; Eye Infections, Fungal; Glaucoma; Humans; Hypertension; Intravitreal Injections; Lipopeptides; Male; Phialophora; Pyrimidines; Triazoles; Vitrectomy; Voriconazole | 2012 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Medication Adherence; Patient Satisfaction; Peptides; Pyrazines; Self Care; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Male; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2012 |
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Topics: Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Pyrroles; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
[Liraglutide: new results in the treatment of type 2 diabetes mellitus].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2012 |
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Young Adult | 2013 |
Liraglutide in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
Fusarium peritonitis concomitant to kidney transplantation successfully managed with voriconazole: case report and review of the literature.
Topics: Antifungal Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fusarium; Humans; Kidney Transplantation; Middle Aged; Mycoses; Organ Transplantation; Peritonitis; Pyrimidines; Triazoles; Voriconazole | 2005 |
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glycine; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Oxazoles; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Models, Animal; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2006 |
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Isoenzymes; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
Diabetes drug update: how 4 new options stack up.
Topics: Administration, Inhalation; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Exenatide; Family Practice; Female; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Islet Amyloid Polypeptide; Male; Peptides; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2007 |
Sitagliptin.
Topics: Adenosine Deaminase Inhibitors; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Prodrugs; Pyrazines; Serine Proteinase Inhibitors; Sitagliptin Phosphate; Triazoles | 2007 |
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Enzyme Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Topics: Animals; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Resistance; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Glycoproteins; Homeostasis; Humans; Hypoglycemic Agents; Islets of Langerhans; Models, Biological; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
[New concepts in the treatment of type 2 diabetes].
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycoproteins; Humans; Isoenzymes; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
Using prandial insulin to achieve glycemic control in type 2 diabetes.
Topics: Algorithms; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Postprandial Period; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
[Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
Topics: Adenosine Deaminase Inhibitors; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2007 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
[Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Incretins; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Molecular Structure; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2008 |
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting | 2008 |
Managed care perspective on three new agents for type 2 diabetes.
Topics: Amyloid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Managed Care Programs; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms | 2008 |
179 trial(s) available for triazoles and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Topics: Animals; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Glucagon-Like Peptide 1; Glycosides; Humans; Hypoglycemic Agents; Mice; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Triazoles | 2013 |
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2013 |
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol; Japan; Linear Models; Male; Middle Aged; Piperidines; Prospective Studies; Pyrazines; Regional Blood Flow; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Uracil; Vasodilation | 2013 |
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.
Topics: Administration, Oral; Argentina; Blood Glucose; Body Weight; Canada; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; India; Insulin, Long-Acting; Male; Mexico; Middle Aged; Pyrazines; Sitagliptin Phosphate; South Africa; Treatment Outcome; Triazoles; Turkey; United States | 2013 |
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Young Adult | 2013 |
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Middle Aged; Pioglitazone; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inpatients; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2014 |
Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
Topics: Aged; Asian People; Blood Glucose; Blood Glucose Self-Monitoring; Body Mass Index; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2013 |
A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Topics: Adult; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxidative Stress; Patient Compliance; Prospective Studies; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2013 |
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss | 2014 |
Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes.
Topics: Aged; Asian People; Blood Glucose; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Inositol; Insulin; Isoindoles; Male; Middle Aged; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles | 2013 |
Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycemic Index; Humans; Hypoglycemic Agents; Inflammation Mediators; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss | 2014 |
Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gene Expression Regulation; Glucose; Humans; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Chemokine CXCL12; Cross-Over Studies; Cyclic AMP; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Piperidines; Pyrazines; Receptor, Angiotensin, Type 1; Sitagliptin Phosphate; Triazoles; Up-Regulation; Uracil | 2014 |
Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Confidence Intervals; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Isoindoles; Male; Middle Aged; Postprandial Period; Prospective Studies; Pyrazines; Reference Values; Severity of Illness Index; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Gastric Emptying; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles | 2014 |
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Glucocorticoids; Glucose Intolerance; Humans; Insulin Resistance; Islets of Langerhans; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Prednisolone; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i
Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastrointestinal Agents; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography, Doppler; Echocardiography, Stress; Electrocardiography; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Heart Ventricles; Humans; Male; Myocardial Ischemia; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Stroke Volume; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left | 2014 |
Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles | 2014 |
Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Adult; Aged; Asian People; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Interleukin-8; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vascular Cell Adhesion Molecule-1 | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles | 2014 |
The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides | 2013 |
Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Infusions, Subcutaneous; Insulin; Insulin Infusion Systems; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Analysis of Variance; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles | 2013 |
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Energy Intake; Gastric Inhibitory Polypeptide; Gastrointestinal Motility; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles | 2014 |
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazines; Triazoles | 2014 |
Glycated albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles | 2014 |
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study.
Topics: Adult; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Prospective Studies; Pyrazines; Research Design; Sitagliptin Phosphate; Triazoles | 2014 |
Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
Topics: Acarbose; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Female; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Isoindoles; Male; Middle Aged; Prospective Studies; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles | 2014 |
A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study.
Topics: Adiponectin; Aged; Asian People; Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2014 |
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss | 2014 |
Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Carotid Arteries; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Tunica Intima; Ultrasonography | 2014 |
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.
Topics: Activation, Metabolic; Adult; Alanine Transaminase; Area Under Curve; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Evoked Potentials, Somatosensory; Fasting; Female; Food, Formulated; gamma-Glutamyltransferase; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Statistics, Nonparametric; Triazoles; Triglycerides | 2014 |
Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin.
Topics: Adult; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Peptides; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Venoms; Young Adult | 2014 |
Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cell Adhesion Molecules; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; E-Selectin; Endothelium, Vascular; Female; Glucagon-Like Peptide 1; Humans; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Phospholipases A2, Secretory; Pyrazines; Sitagliptin Phosphate; Solubility; Triazoles | 2014 |
The amino acid response to a mixed meal in patients with type 2 diabetes: effect of sitagliptin treatment.
Topics: Adult; Aged; Amino Acids; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Humans; Hydroxybutyrates; Insulin; Insulin Resistance; Male; Meals; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Receptors, Glucagon; Renal Insufficiency; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes.
Topics: Apolipoprotein B-48; Apolipoproteins; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides | 2014 |
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycoside Hydrolase Inhibitors; Humans; Inositol; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult | 2014 |
Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Malondialdehyde; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Japan; Kidney; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Up-Regulation | 2015 |
[Effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus].
Topics: Blood Glucose; Body Mass Index; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Intra-Abdominal Fat; Lipid Metabolism; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Isoindoles; Middle Aged; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
The durability of sitagliptin in elderly patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Body Mass Index; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Diagnostic Techniques, Ophthalmological; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Urinalysis | 2014 |
Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incretins; Intra-Abdominal Fat; Japan; Male; Middle Aged; Overweight; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
Topics: Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2014 |
More effective DPP4 inhibitors as antidiabetics based on sitagliptin applied QSAR and clinical methods.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Female; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Male; Middle Aged; Models, Molecular; Pyrazines; Quantitative Structure-Activity Relationship; Romania; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Isoindoles; Male; Middle Aged; Postprandial Period; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Heart Diseases; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Topics: Active Transport, Cell Nucleus; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Benzylamines; Biopsy; Blood Glucose; Blood Transfusion; Cholesterol, LDL; Combined Modality Therapy; Cyclams; Diabetes Mellitus, Type 2; Disease Progression; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Glucosides; Glycated Hemoglobin; Granulocyte Colony-Stimulating Factor; Hamstring Muscles; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Hydrazines; Immunohistochemistry; Insulin-Secreting Cells; Leg; Male; Middle Aged; Muscle Strength; Neoplasms; Peripheral Blood Stem Cell Transplantation; Range of Motion, Articular; Recurrence; Remission Induction; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Soccer; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Triazoles; Young Adult | 2015 |
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
Topics: Aged; Blood Glucose; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Placebos; Pyrazines; Renal Insufficiency, Chronic; Severity of Illness Index; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Stomach; Triazoles; Venoms | 2008 |
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
Topics: Adult; Aged; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; India; Korea; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Topics: Administration, Oral; Aged; Area Under Curve; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Half-Life; Hepatic Insufficiency; Humans; Liver Function Tests; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2009 |
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Middle Aged; Patient Selection; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult | 2009 |
Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Humans; Hypoglycemic Agents; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2009 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Resistin; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Tumor Necrosis Factor-alpha | 2010 |
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2010 |
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2010 |
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
Topics: Administration, Oral; Adult; Aged; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelial Cells; Enzyme Activation; Female; Hematopoietic Stem Cells; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pilot Projects; Pyrazines; Receptors, CXCR4; Sitagliptin Phosphate; Triazoles | 2010 |
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Peptide YY; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes].
Topics: Adult; Aged; Aged, 80 and over; Belgium; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Satisfaction; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Treatment Outcome; Triazoles; Young Adult | 2010 |
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2010 |
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Food; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Kinetics; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid A; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Topics: Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enalapril; Female; Heart Rate; Hemodynamics; Humans; Insulin; Male; Metabolic Syndrome; Middle Aged; Peptidyl-Dipeptidase A; Prospective Studies; Pyrazines; Renal Circulation; Sitagliptin Phosphate; Sodium; Triazoles | 2010 |
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pilot Projects; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2011 |
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2011 |
Sitagliptin reduces albuminuria in patients with type 2 diabetes.
Topics: Albuminuria; Anti-Inflammatory Agents; Blood Pressure; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2011 |
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Female; Health Status; Humans; Hypoglycemic Agents; Male; Mental Health; Middle Aged; Patient Satisfaction; Peptides; Pioglitazone; Pyrazines; Quality of Life; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Topics: Administration, Oral; Adult; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Research Design; Sitagliptin Phosphate; Statistics as Topic; Triazoles; Young Adult | 2011 |
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypertension; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2011 |
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2011 |
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2011 |
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Male; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles | 2011 |
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
[Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].
Topics: Austria; Diabetes Mellitus, Type 2; Drug Tolerance; Female; Humans; Male; Metformin; Middle Aged; Prevalence; Primary Health Care; Prospective Studies; Pyrazines; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Weight Gain | 2011 |
Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
Topics: Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2011 |
The metabolic syndrome influences the response to incretin-based therapies.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2011 |
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients.
Topics: Administration, Oral; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glutamine; Humans; Hyperglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms; Young Adult | 2011 |
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
Topics: Age Factors; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Insulin; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.
Topics: Aged; Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Female; Ghrelin; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Turkey | 2011 |
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Food-Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.
Topics: Adult; Aged; Asia; Asian People; Biomarkers; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Substitution; Fasting; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Islam; Male; Middle Aged; Middle East; Pyrazines; Residence Characteristics; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Young Adult | 2011 |
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2012 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.
Topics: Administration, Oral; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Male; Middle Aged; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti
Topics: Adolescent; Adult; Aged; Argentina; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Germany; Glycated Hemoglobin; Greece; Humans; Hypoglycemia; Hypoglycemic Agents; India; Male; Metformin; Mexico; Middle Aged; Peptides; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2012 |
Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Topics: Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2012 |
Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Waist Circumference | 2012 |
The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Stiffness; Young Adult | 2012 |
Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2012 |
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections | 2012 |
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Triazoles | 2012 |
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Antifungal Agents; Blood Glucose; Canagliflozin; Candida; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Vagina | 2012 |
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
Topics: Abdominal Pain; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Diarrhea; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Fasting; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Inflammation; Interleukin-18; Interleukin-6; Male; Metformin; Middle Aged; Nitriles; Oxidative Stress; Postprandial Period; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2012 |
Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemia; Hypoglycemic Agents; India; Islam; Malaysia; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Young Adult | 2012 |
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Sitagliptin exerts an antinflammatory action.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blotting, Western; C-Reactive Protein; Cell Separation; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; I-kappa B Kinase; Interleukin-6; Male; MAP Kinase Kinase 4; Middle Aged; Monocytes; Prospective Studies; Pyrazines; Receptors, CCR2; Sitagliptin Phosphate; Toll-Like Receptor 2; Toll-Like Receptor 4; Triazoles; Tumor Necrosis Factor-alpha | 2012 |
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2012 |
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Triazoles | 2012 |
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult | 2012 |
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Metformin; Nausea; Patient Satisfaction; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Weight Loss | 2013 |
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; C-Peptide; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Japan; Male; Middle Aged; Monitoring, Ambulatory; Natriuretic Peptide, Brain; Nitriles; Pilot Projects; Plasminogen Activator Inhibitor 1; Postprandial Period; Predictive Value of Tests; Pyrazines; Pyrrolidines; Serum Albumin; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2012 |
[Efficacy of tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China].
Topics: Adult; Aged; Aged, 80 and over; China; Chromium; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Picolinic Acids; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients.
Topics: Aged; Asian People; Body Mass Index; Body Weight; C-Peptide; Demography; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Pyrazines; ROC Curve; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Italy; Lipids; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Topics: Blood Glucose; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Inflammation; Interleukin-10; Interleukin-6; Leukocytes, Mononuclear; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrazines; Regression Analysis; Serum Amyloid A Protein; Sitagliptin Phosphate; Triazoles; Tumor Necrosis Factor-alpha | 2013 |
The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.
Topics: Adiponectin; Aged; Aged, 80 and over; Atherosclerosis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Nitroglycerin; Prospective Studies; Pyrazines; Regression Analysis; Sitagliptin Phosphate; Triazoles; Vasodilation; Vasodilator Agents | 2012 |
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Pyrazines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles | 2013 |
Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics.
Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Research Design; Sitagliptin Phosphate; Triazoles | 2012 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrazines; Pyrimidines; Republic of Korea; Risk Reduction Behavior; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.
Topics: Acute Coronary Syndrome; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Pyrazines; Renal Dialysis; Sitagliptin Phosphate; Triazoles | 2013 |
Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Radioimmunoassay; Sitagliptin Phosphate; Triazoles; Xylose | 2013 |
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
Topics: Adamantane; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Inflammation; Nitriles; Oxidative Stress; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Tyrosine; Vildagliptin | 2013 |
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Topics: Administration, Oral; Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Glucagon-Like Peptide 1; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Male; Middle Aged; Pyrazines; Reference Values; Sitagliptin Phosphate; Triazoles | 2006 |
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Topics: Adenosine Deaminase Inhibitors; Adult; Area Under Curve; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2006 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Placebos; Proinsulin; Protease Inhibitors; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Triazoles | 2006 |
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2006 |
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Patient Selection; Placebos; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Triazoles | 2007 |
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.
Topics: Adult; Age of Onset; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Placebos; Pyrazines; Safety; Sitagliptin Phosphate; Triazoles | 2008 |
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Triglycerides | 2008 |
253 other study(ies) available for triazoles and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Activation of HIF1α Rescues the Hypoxic Response and Reverses Metabolic Dysfunction in the Diabetic Heart.
Topics: Adaptation, Physiological; Anemia, Sickle Cell; Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Energy Metabolism; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin Resistance; Myocytes, Cardiac; Oxygen; Pluripotent Stem Cells; Pyrazoles; Rats; Triazoles | 2021 |
A 67-Year-Old Male Patient With COVID-19 With Worsening Respiratory Function and Acute Kidney Failure.
Topics: Acute Kidney Injury; Aged; Amphotericin B; Antibodies, Monoclonal, Humanized; Antifungal Agents; Atrial Fibrillation; Bronchoscopy; COVID-19; Dexamethasone; Diabetes Mellitus, Type 2; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mucormycosis; Nitriles; Obesity; Oxygen Inhalation Therapy; Pulmonary Aspergillosis; Pyridines; Respiration, Artificial; SARS-CoV-2; Smoking; Tomography, X-Ray Computed; Triazoles; Voriconazole | 2022 |
Cyanoacetohydrazide linked to 1,2,3-triazole derivatives: a new class of α-glucosidase inhibitors.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Kinetics; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Triazoles | 2022 |
Coumarin-4-yl-1,2,3-triazol-4-yl-methyl-thiazolidine-2,4-diones: Synthesis, glucose uptake activity and cytotoxic evaluation.
Topics: Coumarins; Diabetes Mellitus, Type 2; Glucose; HEK293 Cells; Humans; Molecular Docking Simulation; Thiazolidines; Triazoles | 2023 |
2,5-Disubstituted furan derivatives containing imidazole, triazole or tetrazole moiety as potent α-glucosidase inhibitors.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; HEK293 Cells; Humans; Hypoglycemic Agents; Imidazoles; Kinetics; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Tetrazoles; Triazoles | 2023 |
Design, synthesis, in vitro anti-α-glucosidase evaluations, and computational studies of new phthalimide-phenoxy-1,2,3-triazole-N-phenyl (or benzyl) acetamides as potential anti-diabetic agents.
Topics: Acetamides; alpha-Glucosidases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Kinetics; Molecular Docking Simulation; Molecular Structure; Phthalimides; Structure-Activity Relationship; Triazoles | 2023 |
Design, synthesis, in vitro, and in silico evaluations of benzo[d]imidazole-amide-1,2,3-triazole-N-arylacetamide hybrids as new antidiabetic agents targeting α-glucosidase.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imidazoles; Kinetics; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Triazoles | 2023 |
Synthesis of a 1,2,3-bistriazole derivative of embelin and evaluation of its effect on high-fat diet fed-streptozotocin-induced type 2 diabetes in rats and molecular docking studies.
Topics: Adipose Tissue; Animals; Benzoquinones; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucose Tolerance Test; Glucose Transporter Type 4; Insulin; Molecular Docking Simulation; PPAR gamma; Rats; Streptozocin; Triazoles | 2020 |
Primary cutaneous mucormycosis of the abdomen at the site of repeated insulin injections.
Topics: Abdomen; Aged; Anti-Bacterial Agents; Antifungal Agents; Dermatomycoses; Diabetes Mellitus, Type 2; Female; Humans; Immunocompromised Host; Injection Site Reaction; Injections, Subcutaneous; Insulin; Lung Neoplasms; Mucormycosis; Necrosis; Nitriles; Pyridines; Triazoles; Vancomycin | 2020 |
High-fat diet increased NADPH-oxidase-related oxidative stress and aggravated LPS-induced intestine injury.
Topics: Adsorption; Animals; Benzoxazoles; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Acid-Binding Proteins; Humans; Intestines; Lipopolysaccharides; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; NADP; NADPH Oxidases; Obesity; Oxidation-Reduction; Oxidative Stress; Permeability; Reactive Oxygen Species; Tight Junction Proteins; Tight Junctions; Triazoles | 2020 |
Tankyrase inhibition ameliorates lipid disorder via suppression of PGC-1α PARylation in db/db mice.
Topics: Abdominal Fat; Adipose Tissue, White; Animals; Body Weight; Diabetes Mellitus, Type 2; Dyslipidemias; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Obesity; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Poly ADP Ribosylation; Sulfones; Tankyrases; Triazoles | 2020 |
Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia.
Topics: Aged; Azepines; Diabetes Mellitus, Type 2; Drug Chronotherapy; Female; Humans; Male; Prospective Studies; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Triazoles | 2020 |
BRD4 inhibition by JQ1 prevents high-fat diet-induced diabetic cardiomyopathy by activating PINK1/Parkin-mediated mitophagy in vivo.
Topics: Animals; Animals, Newborn; Azepines; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diet, High-Fat; Gene Deletion; Mice, Inbred C57BL; Mitochondria, Heart; Mitophagy; Nuclear Proteins; Promoter Regions, Genetic; Protein Kinases; Transcription Factors; Triazoles; Ubiquitin-Protein Ligases; Up-Regulation | 2020 |
Syndrome of inappropriate antidiuretic hormone secretion induced by suvorexant: a case report.
Topics: Aged; Azepines; Diabetes Mellitus, Type 2; Humans; Inappropriate ADH Syndrome; Male; Triazoles | 2021 |
van der Waals interactions govern C-β-d-glucopyranosyl triazoles' nM inhibitory potency in human liver glycogen phosphorylase.
Topics: Binding Sites; Catalytic Domain; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycogen Phosphorylase; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Kinetics; Liver; Triazoles | 2017 |
Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dogs; Drug Discovery; Humans; Hypoglycemic Agents; Male; Pyridines; Rats; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Triazoles | 2018 |
Discovery and Biological Evaluation of Potent and Orally Active Human 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Type 2 Diabetes Mellitus.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; HEK293 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Obese; Molecular Structure; Structure-Activity Relationship; Triazoles | 2019 |
Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Pilot Projects; Postprandial Period; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Effects of sitagliptin beyond glycemic control: focus on quality of life.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycemic Index; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrazines; Quality of Life; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
[Hemoptysis complicating bronchopulmonary mucormycosis in a diabetic patient].
Topics: Aged, 80 and over; Amphotericin B; Combined Modality Therapy; Diabetes Mellitus, Type 2; Hemoptysis; Humans; Lung Diseases, Fungal; Male; Mucormycosis; Opportunistic Infections; Pneumonectomy; Triazoles | 2013 |
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Topics: Acute Disease; Adolescent; Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Hospitalization; Humans; Logistic Models; Male; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
Topics: Acute Disease; Animals; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Exenatide; Humans; Hypoglycemic Agents; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
DPP4 inhibitor-induced polyarthritis: a report of three cases.
Topics: Adamantane; Arthritis; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
Sitagliptin--another option for managing type 2 diabetes in dialysis patients?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Pancreatitis associated with incretin-based therapies.
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Incretins; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
Topics: Adenoma; Adolescent; Adult; Aged; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hyperplasia; Incretins; Insulin-Secreting Cells; Male; Middle Aged; Neuroendocrine Tumors; Organ Size; Pancreas; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Length of Stay; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Pyrazines; Retrospective Studies; Secondary Prevention; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Substitution; Glucagon-Like Peptide 1; Glycemic Index; Health Care Costs; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Failure; Triazoles; United States | 2013 |
Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database.
Topics: Administration, Oral; Adult; Age Distribution; Diabetes Mellitus, Type 2; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; United States | 2013 |
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
Topics: Adamantane; Animals; Behavior, Animal; Brain; Cognition Disorders; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Insulin Resistance; Male; Maze Learning; Memory; Memory Disorders; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
Topics: Comparative Effectiveness Research; Confounding Factors, Epidemiologic; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypoglycemic Agents; Insurance, Health; Male; Middle Aged; Myocardial Ischemia; Practice Guidelines as Topic; Propensity Score; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; United States | 2013 |
Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Should we be reassured about sitagliptin?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Pyrazines; Triazoles | 2013 |
[Diabetes treatment in patients with chronic kidney disease].
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Kidney Function Tests; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.
Topics: Animals; C-Peptide; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Streptozocin; Treatment Outcome; Triazoles; Umbilical Cord | 2014 |
Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Exenatide; Female; Health Care Costs; Humans; Hypoglycemic Agents; Linear Models; Male; Medicare Part D; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult | 2013 |
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles | 2013 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hypoglycemic Agents; Inflammation; Logistic Models; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Hemizygote; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Male; Metformin; Mice; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Pancreatitis; Plaque, Amyloid; Pyrazines; Random Allocation; Recombinant Proteins; Sitagliptin Phosphate; Time Factors; Triazoles | 2013 |
Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Pyrazines; Triazoles | 2013 |
Authors' reply to de Oliveira.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Pyrazines; Triazoles | 2013 |
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Nitriles; Pyrazines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study.
Topics: Aged; Blood Glucose; Chromosome Aberrations; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Micronuclei, Chromosome-Defective; Middle Aged; Pilot Projects; Pioglitazone; Pyrazines; Rosiglitazone; Sister Chromatid Exchange; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms | 2014 |
An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
Topics: Adolescent; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hyperplasia; Hypoglycemic Agents; Incretins; Male; Middle Aged; Models, Statistical; Pancreas; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Tissue Banks; Triazoles; Venoms; Young Adult | 2013 |
Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Arthritis; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Sitagliptin: results from clinical practice.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
In reply to 'Primary objective of study of sitagliptin in patients with ESRD on dialysis'.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Triazoles | 2013 |
Primary objective of study of sitagliptin in patients with ESRD on dialysis.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Triazoles | 2013 |
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Topics: Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2014 |
The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.
Topics: Animals; Blood Glucose; Body Weight; Bone and Bones; Cell Differentiation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Histocytochemistry; Male; Mice; Osteoblasts; Polymerase Chain Reaction; RNA; Triazoles; X-Ray Microtomography | 2014 |
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
Topics: Belgium; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles | 2013 |
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblasts; Fibronectins; Fibrosis; Glucagon-Like Peptide 1; Glucose Intolerance; Hypoglycemic Agents; Insulin; Male; Metformin; Myocardium; Myocytes, Cardiac; PPAR delta; Protein Isoforms; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2013 |
Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1.
Topics: Acetylcholine; Adiponectin; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Hypothalamus; Insulin; Lipids; Male; Memory; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Adiponectin; Sitagliptin Phosphate; Triazoles | 2013 |
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses.
Topics: Adamantane; Adaptive Immunity; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Immunity, Innate; Mice; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; T-Lymphocytes; Triazoles; Vildagliptin | 2014 |
Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats.
Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2014 |
Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Keratins; Ki-67 Antigen; Male; Metformin; Pancreas, Exocrine; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2014 |
Comment on Du Q, Wu B, Wang YJ, et al. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Curr Med Res Opin 2013;29:1487-94.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Triazoles | 2014 |
1-Phenyl-1H- and 2-phenyl-2H-1,2,3-triazol derivatives: design, synthesis and inhibitory effect on alpha-glycosidases.
Topics: Diabetes Mellitus, Type 2; Drug Design; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Magnetic Resonance Spectroscopy; Triazoles | 2014 |
[Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].
Topics: Acarbose; Administration, Oral; Adverse Drug Reaction Reporting Systems; Benzamides; Biguanides; Data Mining; Databases, Pharmaceutical; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Pyrazines; Risk; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2014 |
Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: the ASSIST-K study.
Topics: Adult; Asian People; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles | 2014 |
Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes.
Topics: Aged; Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Japan; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
Questions on therapy with DPP-4 inhibitors and bone homeostasis.
Topics: Animals; Bone and Bones; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Male; Osteoblasts; Triazoles | 2014 |
SGLT2 versus DPP4 inhibitors for type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles | 2013 |
Use of antidiabetic drugs in the U.S., 2003-2012.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Marketing of Health Services; Metformin; Pharmacies; Prescription Drugs; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; United States | 2014 |
Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate.
Topics: Albuminuria; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Management of a prediabetes case with the DPP-4 inhibitor sitagliptin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Middle Aged; Prediabetic State; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A.
Topics: Amino Acid Sequence; Conserved Sequence; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hydrogen Bonding; Hypoglycemic Agents; Ligands; Molecular Dynamics Simulation; Molecular Sequence Data; Oligopeptides; Protein Binding; Protein Processing, Post-Translational; Protein Structure, Secondary; Protein Subunits; Pyrazines; Sitagliptin Phosphate; Surface Properties; Triazoles | 2014 |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Inflammation; Kidney; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Tumor Necrosis Factor-alpha | 2014 |
Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.
Topics: Adult; Aged; Amylases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipase; Male; Middle Aged; Pancreatitis; Pyrazines; Retrospective Studies; Risk Assessment; Sitagliptin Phosphate; Triazoles | 2013 |
Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles | 2014 |
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Health Services; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Models, Economic; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Smoking; Sulfonylurea Compounds; Sweden; Triazoles | 2014 |
Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Male; Pyrazines; Triazoles | 2014 |
Dapagliflozin--do we need it registered for type 2 diabetes?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles | 2014 |
Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Topics: Animals; Atherosclerosis; Blood Glucose; Carotid Arteries; Chemokine CCL2; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; In Vitro Techniques; Insulin; Linagliptin; Malondialdehyde; NADPH Oxidases; Purines; Pyrazines; Quinazolines; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Vasodilation | 2014 |
Diabetes: safety and efficacy of albiglutide-results from two trials.
Topics: Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Pyrazines; Sulfonylurea Compounds; Triazoles | 2014 |
Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
Topics: Administration, Oral; Aged; Algorithms; Biomarkers; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Japan; Male; Proinsulin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Greece; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2014 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
Topics: Adamantane; Adult; Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
Comment and response to: dapagliflozin - do we need it registered for type 2 diabetes?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles | 2014 |
Plasma gelsolin levels decrease in diabetic state and increase upon treatment with F-actin depolymerizing versions of gelsolin.
Topics: Actins; Adult; Animals; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Down-Regulation; Female; Gelsolin; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Peptide Fragments; Polymerization; Pyrazines; Recombinant Proteins; Sitagliptin Phosphate; Streptozocin; Time Factors; Triazoles | 2014 |
A novel data-mining approach leveraging social media to monitor consumer opinion of sitagliptin.
Topics: Attitude to Health; Consumer Behavior; Data Mining; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Information Dissemination; Natural Language Processing; Patient Satisfaction; Public Opinion; Pyrazines; Sitagliptin Phosphate; Social Media; Triazoles; Vocabulary, Controlled | 2015 |
Author’s response.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles | 2014 |
Expression of CD73 and A2A receptors in cells from subjects with obesity and type 2 diabetes mellitus.
Topics: 5'-Nucleotidase; Adenosine; Adult; Antigens, CD; Apoptosis; Apyrase; Body Mass Index; CD8-Positive T-Lymphocytes; Diabetes Mellitus, Type 2; Gene Expression Regulation; GPI-Linked Proteins; Humans; Inflammation; Lymphocyte Subsets; Lymphocytes; Obesity; Phenethylamines; Receptor, Adenosine A2A; Triazines; Triazoles | 2015 |
Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2015 |
[Sitagliptin in diabetes: Severe side effects are rare].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
[Type 2 diabetes: Cardiovascular long-term safety of sitagliptin demonstrated].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and other 'gliptins'--why prescribe them?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2016 |
Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
Topics: Animals; Blood Glucose; Click Chemistry; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Models, Molecular; Molecular Structure; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Triazoles | 2016 |
Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice.
Topics: Adipose Tissue; Animals; Azepines; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucose; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Orexin Receptor Antagonists; Orexins; Receptors, Leptin; Sleep; Triazoles; Triglycerides; Wakefulness | 2016 |
Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.
Topics: Animals; Chemistry Techniques, Synthetic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Hypoglycemic Agents; Inhibitory Concentration 50; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Protein Conformation; Structure-Activity Relationship; Triazoles; Uracil | 2016 |
Aceruloplasminaemia: a disorder of diabetes and neurodegeneration.
Topics: Adult; Benzoates; Brain; Ceruloplasmin; Copper; Deferasirox; Diabetes Mellitus, Type 2; Diagnosis, Differential; Ferritins; Humans; Insulin; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Magnetic Resonance Imaging; Male; Neurodegenerative Diseases; Triazoles | 2017 |
Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Design; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Triazines; Triazoles | 2017 |
Three new drugs for type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2008 |
[Sitagliptin].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Patient Selection; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles | 2008 |
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Treatment Outcome; Triazoles; Vildagliptin | 2009 |
Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cost Savings; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Emergency Service, Hospital; Exenatide; Female; Glycated Hemoglobin; Health Care Costs; Health Services Research; Humans; Hypoglycemic Agents; Insurance Claim Review; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Regression Analysis; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States; Venoms | 2009 |
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2009 |
Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase.
Topics: Activating Transcription Factor 2; Animals; Binding Sites; Diabetes Mellitus, Type 2; Drug Design; HeLa Cells; Humans; Hypoglycemic Agents; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Male; Mice; Phosphorylation; Protein Binding; Structure-Activity Relationship; Substrate Specificity; Thiadiazoles; Thiazoles; Triazoles | 2009 |
Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2009 |
Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Europe; Humans; Pyrazines; Sulfonylurea Compounds; Triazoles | 2009 |
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.
Topics: Amyloid; Animals; Animals, Genetically Modified; Arginine; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Clamp Technique; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Islet Amyloid Polypeptide; Islets of Langerhans; Metformin; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles | 2009 |
By the way, doctor. I've had type 2 diabetes for 12 years; I'm now 81. I take metformin plus Januvia. My doctor has never suggested that I monitor myself on a daily basis with a meter. My hemoglobin A1c has been creeping up and is now at 7. Should I
Topics: Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Topics: Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Drug Synergism; Europe; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Sulfonylurea Compounds; Triazoles | 2009 |
Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic.
Topics: Ambulatory Care Facilities; Cohort Studies; Cross-Sectional Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Drug Utilization Review; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney Function Tests; Medication Errors; Pharmacists; Private Sector; Professional Role; Pyrazines; Renal Insufficiency; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States | 2009 |
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Ki-67 Antigen; Lipids; Liver; Male; Mice; Mice, Inbred ICR; Organ Size; Pyrazines; Sitagliptin Phosphate; Triazoles; Triglycerides | 2009 |
Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon.
Topics: Adamantane; Cinnamomum zeylanicum; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2009 |
[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2009 |
[Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Pyrazines; Reference Values; Sitagliptin Phosphate; Triazoles | 2009 |
[Combination antidiabetic therapy. Better control of blood glucose values].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2009 |
Initial therapy for type 2 diabetes. Examination of a combination approach.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Practice; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nurse Practitioners; Practice Guidelines as Topic; Primary Health Care; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Metformin; Models, Theoretical; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.
Topics: Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Peptides; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Elevated hepatic enzymes potentially associated with sitagliptin.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Humans; Liver; Liver Function Tests; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Lipopolysaccharide Receptors; Male; Membrane Proteins; Middle Aged; Monocytes; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.
Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Hypertension; Kidney; Male; Metabolic Syndrome; Proteinuria; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Sitagliptin Phosphate; Triazoles; Vasoconstriction; Vasoconstrictor Agents | 2010 |
New therapeutic options: management strategies to optimize glycemic control.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Use of posaconazole in the treatment of infective rhinocerebral mucormycosis.
Topics: Antifungal Agents; Brain Diseases; Diabetes Mellitus, Type 2; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mucormycosis; Orbital Diseases; Paranasal Sinus Diseases; Rhizopus; Triazoles | 2010 |
Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Topics: Adult; Age Factors; Aged; Body Mass Index; Body Weight; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insurance Claim Review; Lipids; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sex Factors; Sitagliptin Phosphate; Socioeconomic Factors; Triazoles; Venoms | 2010 |
[New hypoglycemic agents in type 2 diabetes].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2010 |
Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Topics: Administration, Oral; Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Electronic Health Records; Humans; Hyperglycemia; Hypoglycemic Agents; Individuality; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States | 2010 |
Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report.
Topics: Anti-Obesity Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Lactones; Middle Aged; Orlistat; Pancreatitis; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Irbesartan; Pyrazines; Sitagliptin Phosphate; Tetrazoles; Treatment Outcome; Triazoles | 2010 |
Choosing among the incretin agents and why it matters.
Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Individualised incretin-based treatment for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Hypersensitivity; Female; Glucagon-Like Peptide 1; Humans; Incidence; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States | 2010 |
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glycated Hemoglobin; Insulin; Insulin Resistance; Interleukin-1beta; Lipids; Male; Oxidative Stress; Pancreas; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2010 |
Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Enalapril; Heart Rate; Hemodynamics; Humans; Metabolic Syndrome; Models, Biological; Peptidyl-Dipeptidase A; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pancreatitis; Peptides; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes.
Topics: Animals; Apoptosis; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA Fragmentation; Female; Glutathione; Glutathione Peroxidase; Kidney; Kidney Diseases; Lipid Peroxidation; Male; Oxidative Stress; Peroxidase; Pyrazines; Rats; Rats, Wistar; Reperfusion Injury; Sitagliptin Phosphate; Superoxide Dismutase; Triazoles; Xanthine Oxidase | 2011 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Health Status; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Acceptance of Health Care; Pyrazines; Sitagliptin Phosphate; Triazoles; United States | 2010 |
Severe leucopenia associated with Sitagliptin use.
Topics: Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Leukopenia; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
[New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2010 |
Organ-specific dietary fatty acid uptake in humans using positron emission tomography coupled to computed tomography.
Topics: Adolescent; Adult; Animals; Blood Glucose; Chylomicrons; Diabetes Mellitus, Type 2; Dietary Fats; Fatty Acids; Fatty Acids, Nonesterified; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Palmitates; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Wistar; Tomography, Emission-Computed; Triazoles; Triglycerides; Whole-Body Counting; Young Adult | 2011 |
Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; India; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Statistics, Nonparametric; Triazoles; Triglycerides | 2011 |
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Lipoproteins; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
Sitagliptin manufacture: a compelling tale of green chemistry, process intensification, and industrial asymmetric catalysis.
Topics: Biocatalysis; Diabetes Mellitus, Type 2; Green Chemistry Technology; Humans; Pyrazines; Ruthenium; Sitagliptin Phosphate; Transaminases; Triazoles | 2011 |
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Topics: Adverse Drug Reaction Reporting Systems; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Odds Ratio; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; United States; United States Food and Drug Administration; Venoms | 2011 |
Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Feeding Behavior; Glucagon; Glucagon-Like Peptide 1; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2011 |
Synthesis of variously coupled conjugates of D-glucose, 1,3,4-oxadiazole, and 1,2,3-triazole for inhibition of glycogen phosphorylase.
Topics: Alkynes; Animals; Azides; Catalysis; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucose; Glycoconjugates; Glycogen Phosphorylase, Muscle Form; Humans; Kinetics; Oxadiazoles; Phosphorylase b; Propionates; Rabbits; Triazoles | 2011 |
Journal withdraws article after complaints from drug manufacturers.
Topics: Diabetes Mellitus, Type 2; Drug Industry; Editorial Policies; Exenatide; Humans; Hypoglycemic Agents; Incretins; Pancreatitis; Peptides; Periodicals as Topic; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
A case of drug-induced hepatic injury associated with sitagliptin.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Jaundice; Liver; Male; Microscopy, Electron, Transmission; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
A diabetes drug, sitagliptin, also has a potential to prevent diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2011 |
[Incretin enhancer: sitagliptin].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
DPP-IV inhibitor may affect spermatogenesis.
Topics: Adult; Amoxapine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ejaculation; Humans; Male; Neurotransmitter Uptake Inhibitors; Pyrazines; Semen Analysis; Sitagliptin Phosphate; Spermatogenesis; Triazoles | 2011 |
Cerebral mucormycosis in a diabetic man.
Topics: Amphotericin B; Antifungal Agents; Biopsy; Brain Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diagnosis, Differential; Drug Therapy, Combination; Endoscopy; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mucormycosis; Tomography, X-Ray Computed; Triazoles | 2011 |
GLP-1-based therapies: the dilemma of uncertainty.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; Uncertainty; Venoms | 2011 |
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2011 |
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; United Kingdom; Young Adult | 2012 |
Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Middle Aged; Pruritus; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2012 |
Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Thyroid Neoplasms; Triazoles; Venoms | 2011 |
The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Psoriasis; Pyrazines; Sitagliptin Phosphate; T-Lymphocytes; Treatment Outcome; Triazoles | 2012 |
Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Triazoles | 2012 |
Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Japan; Life Style; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease Susceptibility; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infections; Liraglutide; Pancreatitis; Pharmacovigilance; Pioglitazone; Pyrazines; Risk Assessment; Safety-Based Drug Withdrawals; Sitagliptin Phosphate; Species Specificity; Thiazolidinediones; Thyroid Neoplasms; Triazoles; Urinary Bladder Neoplasms | 2012 |
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Insulin; Kidney Glomerulus; Lipid Peroxidation; Lipids; Male; Obesity; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures.
Topics: Alzheimer Disease; Animals; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Male; Neurons; Phosphorylation; Primary Cell Culture; Pyrazines; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Sitagliptin Phosphate; tau Proteins; Triazoles | 2012 |
Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
Topics: Acute Kidney Injury; Adolescent; Adult; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Labeling; Exenatide; Female; Humans; Incidence; Male; Middle Aged; Peptides; Proportional Hazards Models; Pyrazines; Retrospective Studies; Risk Assessment; Sitagliptin Phosphate; Triazoles; Venoms; Young Adult | 2012 |
Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice.
Topics: Animals; Apolipoprotein B-100; Biological Transport; Biomarkers; Blood Glucose; Cholesterol; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Intestinal Absorption; Lipoproteins, HDL; Macrophages; Male; Metformin; Mice; Mice, Obese; Mice, Transgenic; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
Topics: Allylamine; Animals; Anticholesteremic Agents; Apoptosis; Bile Acids and Salts; Blood Glucose; Body Weight; Cell Proliferation; Cell Size; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Diet; Drug Synergism; Fluorescent Antibody Technique; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; In Situ Nick-End Labeling; Insulin; Insulin-Secreting Cells; Ki-67 Antigen; Male; Postprandial Period; Pyrazines; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; RNA, Messenger; Sitagliptin Phosphate; Triazoles | 2012 |
Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Extremities; Female; Humans; Middle Aged; Psoriasis; Pyrazines; Sitagliptin Phosphate; Torso; Triazoles | 2012 |
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
Topics: Adult; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Humans; Hypoglycemic Agents; Long-Term Care; Male; Markov Chains; Middle Aged; Models, Theoretical; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; United States; Venoms | 2012 |
Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study.
Topics: Adult; Aged; Body Mass Index; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Overweight; Pyrazines; Regression Analysis; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Weight Loss | 2012 |
Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Male; Photosensitivity Disorders; Protective Clothing; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
[Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Humans; Islets of Langerhans; Losartan; Male; Mice; Pyrazines; Regeneration; Sitagliptin Phosphate; Stem Cells; Triazoles | 2012 |
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptides; Drinking; Eating; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Immunohistochemistry; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy.
Topics: Aged; Blood Glucose; Blood Pressure; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Weight Gain | 2012 |
Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Immunohistochemistry; Lipid Metabolism; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Choosing a blood-glucose-lowering agent after metformin.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Serum level of soluble CD26/dieptidyl peptidase-4 (DPP-4) activity correlates with other liver disease biomarkers both in Asian and European patients.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Pyrazines; Triazoles | 2012 |
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Topics: Adult; Aged; Aged, 80 and over; Calibration; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Time Factors; Triazoles | 2012 |
Re: Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4).
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Pyrazines; Triazoles | 2012 |
Kinetics studies on the inhibition mechanism of pancreatic α-amylase by glycoconjugated 1H-1,2,3-triazoles: a new class of inhibitors with hypoglycemiant activity.
Topics: Animals; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hypoglycemic Agents; Kinetics; Models, Molecular; Molecular Structure; Pancreatic alpha-Amylases; Structure-Activity Relationship; Swine; Triazoles | 2012 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Markov Chains; Metformin; Outcome Assessment, Health Care; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.
Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Japan; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2012 |
Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.
Topics: Alleles; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Genetic Predisposition to Disease; HLA-DRB1 Chains; Humans; Middle Aged; Pyrazines; Rheumatoid Factor; Sitagliptin Phosphate; Triazoles | 2012 |
Mechanism of action of DPP-4 inhibitors--new insights.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.
Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Female; Hepatocytes; Humans; Male; Middle Aged; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.
Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Obesity; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Satiation; Sitagliptin Phosphate; Triazoles | 2012 |
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Drug Evaluation; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Inflammation; Liraglutide; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pioglitazone; Platelet Count; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2012 |
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Immunoblotting; Lipids; Lipoxins; Male; Membrane Proteins; Mice; Myocardial Infarction; Myocardium; Phosphodiesterase 3 Inhibitors; PTEN Phosphohydrolase; Tetrazoles; Triazoles | 2012 |
Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.
Topics: Adult; Aged; Blood Platelets; Blood Proteins; Calcium; Case-Control Studies; Cells, Cultured; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazines; Sitagliptin Phosphate; Thrombin; Triazoles; Tyrosine | 2012 |
[Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction].
Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Kidney Failure, Chronic; Metabolic Syndrome; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sitagliptin Phosphate; Survival Rate; Triazoles | 2012 |
Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Humans; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Nude; Nateglinide; Peptides; Phenylalanine; Pyrazines; Sitagliptin Phosphate; Specific Pathogen-Free Organisms; Triazoles; Venoms | 2013 |
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Adenoma; Anatomy, Cross-Sectional; Animals; Chlorocebus aethiops; Colon; Colonic Neoplasms; COS Cells; Cyclic AMP; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide-2 Receptor; Hypoglycemic Agents; Intestinal Mucosa; Intestine, Small; Liraglutide; Mice; Mice, Inbred C57BL; Organ Size; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Transfection; Triazoles; Venoms | 2012 |
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin | 2012 |
Cyclic AMP and PKA: how can a lot of good come from the potentially bad? : editorial to: "phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus" by Y
Topics: Animals; Cilostazol; Cyclic AMP; Diabetes Mellitus, Type 2; Male; Myocardial Infarction; Phosphodiesterase 3 Inhibitors; Tetrazoles; Triazoles | 2012 |
Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates.
Topics: Aged; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Blood Coagulation Factors; Bradykinin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypertension; Laryngeal Diseases; Male; Perindopril; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin.
Topics: Acute Kidney Injury; Aged; Back; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ear; Edema; Eosinophilia; Exanthema; Female; Glucocorticoids; Humans; Prednisone; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles | 2013 |
Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles | 2013 |
Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Chi-Square Distribution; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Inflammation Mediators; Linear Models; Logistic Models; Male; Manometry; Middle Aged; Multivariate Analysis; Odds Ratio; Peripheral Arterial Disease; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Dipeptidyl peptidase-4 inhibitors--emerging player for vascular protection.
Topics: Anti-Inflammatory Agents; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Male; Peripheral Arterial Disease; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
Topics: Animals; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Mice; Models, Molecular; Molecular Docking Simulation; Retinoid X Receptors; Tetrahydronaphthalenes; Triazoles | 2013 |
A new method to evaluate spontaneous platelet aggregation in type 2 diabetes by Cellfacts.
Topics: Adenosine Diphosphate; Antioxidants; Azepines; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; In Vitro Techniques; Male; Middle Aged; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Triazoles; Vitamin E | 2003 |
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Binding Sites; Biochemistry; Blood Glucose; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Models, Molecular; Peptide Fragments; Protein Conformation; Protein Precursors; Pyrazines; Rats; Sitagliptin Phosphate; Structure-Activity Relationship; Triazoles | 2005 |
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Disease Models, Animal; Dyslipidemias; Glipizide; Hypoglycemic Agents; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred ICR; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2006 |
(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Biological Availability; Calcium Channels, L-Type; Cell Line; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucose Tolerance Test; Humans; Hypoglycemic Agents; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Microsomes, Liver; Models, Molecular; Muscle Proteins; Muscle, Skeletal; NAV1.5 Voltage-Gated Sodium Channel; Phenylalanine; Protease Inhibitors; Rabbits; Sodium Channels; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2006 |
[DPP-4 inhibition raises incretin levels].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon-Like Peptide 1; Humans; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Oral agents for type 2 diabetes reduce HbA1c, are weight neutral.
Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Animals; Azepines; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Protease Inhibitors; Protein Conformation; Pyrazines; Rats; Rats, Inbred Strains; Sitagliptin Phosphate; Triazoles | 2007 |
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibi
Topics: Animals; Biphenyl Compounds; Cyclohexenes; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Female; Hypoglycemic Agents; Models, Molecular; Rats; Rats, Zucker; Serine Proteinase Inhibitors; Structure-Activity Relationship; Triazoles; X-Ray Diffraction | 2006 |
First-in-class diabetes drug approved.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Diabetes: kicking off the insulin cascade.
Topics: ADP-Ribosylation Factors; Animals; Diabetes Mellitus, Type 2; Drosophila melanogaster; Guanine Nucleotide Exchange Factors; Insulin; Insulin Resistance; Liver; Signal Transduction; Triazoles | 2006 |
Sitagliptin (Januvia) for type 2 diabetes.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Finding new treatments for diabetes--how many, how fast... how good?
Topics: Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Glucagon-Like Peptide 1; Glycoproteins; History, 20th Century; History, 21st Century; Humans; Hypoglycemic Agents; Peptide Fragments; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration | 2007 |
Sitagliptin.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2007 |
Sitagliptin: a viewpoint by Mark S. Kipnes.
Topics: Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Sitagliptin: a viewpoint by Itamar Raz.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
[Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani].
Topics: Antifungal Agents; Cellulitis; Ciclopirox; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Resistance, Multiple, Fungal; Foot Dermatoses; Fusarium; Humans; Imidazoles; Immunocompetence; Itraconazole; Male; Middle Aged; Mozambique; Onychomycosis; Pyridones; Pyrimidines; Recurrence; Toes; Travel; Triazoles; Urea; Voriconazole | 2006 |
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Triazoles | 2007 |
Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole.
Topics: Alcaligenes; Amphotericin B; Amputation, Surgical; Antifungal Agents; Cefazolin; Combined Modality Therapy; Debridement; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Drug Resistance, Multiple, Fungal; Escherichia coli Infections; Fatal Outcome; Fluconazole; Gangrene; Graft Rejection; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Leg; Leg Ulcer; Male; Middle Aged; Mucor; Mucormycosis; Penicillanic Acid; Phosphatidylcholines; Phosphatidylglycerols; Piperacillin; Postoperative Complications; Pyrimidines; Renal Dialysis; Reoperation; Sepsis; Skin Transplantation; Tazobactam; Triazoles; Voriconazole | 2007 |
New treatments for diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin | 2007 |
New treatments for diabetes.
Topics: Adenosine Deaminase Inhibitors; Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2007 |
New treatments for diabetes.
Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration | 2007 |
New treatments for diabetes.
Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Glycoproteins; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration | 2007 |
Sitagliptin/metformin (Janumet) for type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Janumet.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
[New class of oral antidiabetic drugs. Effective in combination with metformin].
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Treatment of type 2 diabetes mellitus and the incretin system.
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; United States; Venoms | 2007 |
Type 2 diabetes: the end of clinical inertia.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Nebulizers and Vaporizers; Peptides; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2007 |
Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Triazoles | 2008 |
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].
Topics: Belgium; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Non-Candida albicans Candida mediastinitis of odontogenic origin in a diabetic patient.
Topics: Adult; Amphotericin B; Antifungal Agents; Candidiasis, Oral; Diabetes Mellitus, Type 2; Female; Humans; Mediastinitis; Opportunistic Infections; Pyrimidines; Triazoles; Voriconazole | 2008 |
2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Adipose Tissue; Animals; Cortisone; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Humans; Hydrocortisone; Hypoglycemic Agents; Ligands; Liver; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Rats; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Triazoles | 2008 |
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Models, Economic; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
[Sitagliptine (Januvia)].
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Incretins; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Pyrazines; Sitagliptin Phosphate; Sympathetic Nervous System; Treatment Outcome; Triazoles | 2008 |
Nefazodone-induced hypoglycemia in a diabetic patient with major depression.
Topics: Antidepressive Agents, Second-Generation; Blood Glucose; Depressive Disorder; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Middle Aged; Piperazines; Triazoles | 1997 |
Possible interaction of zopiclone and nefazodone.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disorder; Diabetes Mellitus, Type 2; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Piperazines; Triazoles | 2001 |